Viral Respiratory Pathogens and Lung Injury

Nicola Clementi,a,b Sreya Ghosh,c Maria De Santis,d Matteo Castelli,a Elena Criscuolo,a Ivan Zanoni,c,e Massimo Clementi,a,b

Nicola Clementi and Sreya Ghosh contributed equally to this article. Author order was determined alphabetically.

Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy
Laboratory of Microbiology and Virology, IRCCS San Raffaele Scientific Institute, Milan, Italy
Harvard Medical School, Boston Children’s Hospital, Division of Immunology, Boston, Massachusetts, USA
Department of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center–IRCCS, Rozzano, Italy
Harvard Medical School, Boston Children’s Hospital, Division of Gastroenterology, Boston, Massachusetts, USA

SUMMARY ................................................................. 1
INTRODUCTION ......................................................... 2
CLINICAL AND LABORATORY FEATURES OF RESPIRATORY VIRAL INFECTIONS ......................................................... 2
Clinical Findings ....................................................... 2
Radiological Presentation and Laboratory Markers .......................... 3
THE RESPIRATORY VIRUSES AND THEIR DIRECT MECHANISMS OF TISSUE DAMAGE ........................................... 5
RNA Viruses ................................................................. 5
Orthomyxoviruses ......................................................... 5
Paramyxoviruses ................................................................. 7
Coronaviruses ................................................................. 8
DNA Viruses ................................................................. 12
Adenoviruses ................................................................. 12
Herpesviruses ............................................................... 13
Human bocaviruses ............................................................... 15
IMMUNE-MEDIATED DAMAGE INDUCED BY RESPIRATORY VIRUSES ................................................................. 15
Protective Role of Immune System against Respiratory Viruses .......... 16
Prevention of respiratory infections ........................................ 17
(i) Airway epithelium ......................................................... 17
(ii) Endothelial cells ......................................................... 18
(iii) Alveolar macrophages ................................................. 18
(iv) Neutrophils ................................................................. 19
(v) Dendritic cells ............................................................. 19
(vi) Monocyte-derived DCs ............................................... 20
(vii) Tissue-resident lymphocytes ....................................... 20
(viii) B cells and T cells ...................................................... 21
Clearance of viral respiratory infections .................................... 22
(i) Interferons and antiviral ISGs ....................................... 22
(ii) Chemokines .............................................................. 23
(iii) Inflammatory cytokines .............................................. 23
(iv) Other antiviral factors .................................................. 24
Role of Immune System in Lung Damage .................................... 25
INVESTIGATIONAL TOOLS TO IMPACT IMMUNE RESPONSES DURING VIRAL INFECTIONS ........................................... 28
The Possible Therapeutic Role of Interferons ................................ 29
The Possible Therapeutic Role of Immunomodulators ................... 31
The Possible Therapeutic Role of Antivirals ................................ 32
Remdesivir ................................................................. 32
Lopinavir-ritonavir ............................................................ 32
Hydroxychloroquine ....................................................... 33
Colchicine ................................................................. 33
Atovaquone-azithromycin .................................................... 33
CONCLUDING REMARKS .......................................... 33
ACKNOWLEDGMENT .................................................. 33
REFERENCES .............................................................. 33
AUTHOR BIOS ............................................................ 45

Copyright © 2021 American Society for Microbiology. All Rights Reserved.
Address correspondence to Nicasio Mancini, mancini.nicasio@hs.it.
Published 31 March 2021
SUMMARY  Several viruses target the human respiratory tract, causing different clinical manifestations spanning from mild upper airway involvement to life-threatening acute respiratory distress syndrome (ARDS). As dramatically evident in the ongoing SARS-CoV-2 pandemic, the clinical picture is not always easily predictable due to the combined effect of direct viral and indirect patient-specific immune-mediated damage. In this review, we discuss the main RNA (orthomyxoviruses, paramyxoviruses, and coronaviruses) and DNA (adenoviruses, herpesviruses, and bocaviruses) viruses with respiratory tropism and their mechanisms of direct and indirect cell damage. We analyze the thin line existing between a protective immune response, capable of limiting viral replication, and an unbalanced, dysregulated immune activation often leading to the most severe complication. Our comprehension of the molecular mechanisms involved is increasing and this should pave the way for the development and clinical use of new tailored immune-based antiviral strategies.

KEYWORDS  COVID-19, SARS-CoV-2, respiratory tract, viral infections

INTRODUCTION  Acute respiratory tract infections are a major public health problem and a leading cause of morbidity and mortality worldwide, especially in children, elderly, and immunocompromised subjects (1). Annually, almost 29 to 59 million people in the United States become infected with influenza viruses and nearly 500 million people experience two or more non-influenza-related viral respiratory tract infections (2). RNA viruses are the predominant agents, and common pathogens include respiratory syncytial viruses, influenza viruses, parainfluenza viruses, metapneumoviruses, rhinoviruses, enteroviruses, and coronaviruses (2). DNA viruses causing respiratory tract involvement include adenoviruses, bocaviruses (3), and reactivating pathogens in immunosuppressed patients, such as herpes simplex virus, cytomegalovirus, and Epstein-Barr virus (4).

Respiratory tract infections usually exhibit a seasonality, occurring typically during late autumn, winter, and early spring. The hypotheses proposed to explain this phenomenon include increased crowding during the cold seasons, lower temperatures and higher humidity increasing the stability of virions outside the body, and chilling, which may increase host susceptibility and vitamin D deficiency due to lower sun exposure (5). Influenza viruses, coronaviruses, and respiratory syncytial viruses show infection peaks in winter, even if epidemiological differences are observed in tropical and subtropical areas and alteration in seasonality occurs during pandemics (5–8). Adenoviruses, bocaviruses, parainfluenza viruses, metapneumoviruses, and rhinoviruses can be detected throughout the year. Seasonal patterns of parainfluenza viruses can be type specific with types 1 and 3 peaking in the fall and spring-summer, respectively. The prevalence of some enteroviruses increases in summer (5).

CLINICAL AND LABORATORY FEATURES OF RESPIRATORY VIRAL INFECTIONS

Clinical Findings  The diseases caused by these different viruses vary from self-limiting upper respiratory tract infections, such as cold, sore throat, or laryngo-tracheo-bronchitis to life-threatening lower respiratory tract infections, such as bronchiolitis, pneumonia, or acute respiratory distress syndrome (ARDS), as well as occasionally disseminated disease. The involvement of lower respiratory tract can occur through one of the following three mechanisms: (i) direct infection of lung cells without sustained virological replication in the upper respiratory tract (this is the case of several influenza viruses featuring preferential tropism for the sialic acids of the deeper airways), (ii) spread in a contiguous fashion from viral infections involving the upper respiratory tract (e.g., coronaviruses), and (iii) hematogenous spread (e.g., cytomegaloviruses) (9).

The severity of each infection and the possible progression from the upper to the lower respiratory tract depend on the intrinsic virulence of the causing virus, on...
possible coinfections, and on patient-related factors such as age, underlying illnesses (i.e., concurring respiratory and cardiovascular comorbidities), or degree of immunodeficiency (10).

Considering age, viral respiratory tract infections are a major killer of young children and elderly people. Moreover, in developing countries the incidence of death among children can be up to five times higher than in developed regions (11). Viruses such as respiratory syncytial virus mostly affect young children, who develop rhinitis, laryngitis, or sinusitis, or neonates, who are at risk for bronchiolitis and pneumonia (12). On the other hand, influenza viruses account for an average of 23,607 annual flu-related deaths, 90% of which occur among persons age 65 or older (3).

Comorbidities significantly worsening the prognosis of respiratory infections include chronic heart or lung diseases, diabetes, kidney or liver diseases, blood disorders, malnutrition, and immune deficiencies (2). Immunocompromised patients include transplant recipients, cancer patients on chemotherapy, rheumatic patients treated with immnosuppressant drugs, and subjects with primary immunodeficiencies or infected with human immunodeficiency virus (2). In the latest categories of patients, respiratory viruses are acquired at the same frequency as in immunocompetent individuals but are associated with prolonged infections, increased progression to lower respiratory tract infections, and a higher mortality (2).

Virus-induced ARDS is not common in immunocompetent patients, but its exact prevalence is not known (13). Pandemic viruses, such as severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in 2002, Middle East respiratory syndrome (MERS) virus in 2012, avian influenza A H5N1 in 1998, influenza A H1N1 in 2009, and recently, the novel coronavirus SARS-CoV-2 in 2019, have a significantly higher frequency of ARDS and higher case fatality rates compared to seasonal viruses (13). In the early phases of SARS-CoV-2 pandemic, up to 30% of hospitalized patients with SARS-CoV-2 disease (COVID-19) progress to ARDS, which is the main cause of mortality (14).

There are no pathognomonic cues for the diagnosis of viral pneumonia as opposed to bacterial pneumonia or other causes of lung disease. Viral pneumonia has a more gradual onset than bacterial pneumonia and more frequent clinical manifestations of concomitant upper respiratory tract infection. Flu-like symptoms, rash or gastrointestinal symptoms, lack of purulent sputum, tachycardia or tachypnea out of proportion to the temperature, paucity of physical findings on pulmonary exam disproportionate to the level of debility, and possible bilateral positive lung findings are also more common in viral pneumonia (9). Immune-mediated interstitial lung diseases (pulmonary fibrosis, sarcoidosis, and hyper-reactive airway disease), lung vascular diseases (pulmonary embolism and pulmonary hypertension), and congestive heart failure should be considered in the differential diagnosis. Laboratory tests in combination with radiography can significantly improve the suspicion of viral pneumonia, while the identification of viruses causing pneumonia is gaining importance considering the new diagnostic tools available.

**Radiological Presentation and Laboratory Markers**

A thorough description of the radiological findings and the laboratory markers observed in the course of viral pneumonia is well beyond the scope of this review, but nonetheless their role in its clinical diagnosis deserves a general overview.

Chest X-ray is the most widely used imaging technique in the diagnosis of lower respiratory tract infections, followed by computed tomography (CT). A chest radiograph can establish the presence of pneumonia, determine its extent and location, and assess the response to treatment (15). It can also diagnose complications like pleural effusion or pneumothorax. No findings are pathognomonic for different pneumonia etiologies, since there is a substantial overlap in chest X-ray findings between bacterial and viral pneumonia. Features that are suggestive of bacterial pneumonia include alveolar infiltrates with lobar consolidation and coexistent pleural effusion. Features that are more suggestive of viral pneumonia include bilateral interstitial infiltrates with patchy distribution (9). Several chest X-ray-based machine-learning approaches for the detection and differentiation of viral form bacterial pneumonia are under development with
Encouraging results. A recent meta-analysis calculated 89% sensitivity and 89% specificity of different automated algorithms using chest X-ray images in the differential diagnosis of viral pneumonia but also evidenced several methodological concerns, which still hamper their transfer into the clinic (16).

A CT scan is not used for the initial evaluation of pneumonia but may be used when the clinical suspicion of viral pneumonia is high and chest X-ray is negative to better characterize the pneumonia pattern, to look for complications, or to detect underlying lung diseases. Pneumonia can appear as lobar pneumonia (confluent areas of consolidation, which are usually confined to one segment or lobe and frequently found in bacterial pneumonia), as bronchopneumonia (centrilobular nodules that coalesce to cause consolidation and involve one or more lobes), and as interstitial pneumonia (involvement of bronchiolar wall and pulmonary interstitium leading to septal thickening, micronodules, and areas of ground-glass opacities). The latter is the most common radiological presentation of viral pneumonia (15). Also, in this case, there are no pathognomonic patterns of different viral pneumonia. Ground-glass opacity seems to be more frequently noticed in patients with adenovirus pneumonia than in patients with other viral infections, while influenza viruses diffusely invade the respiratory epithelium, resulting in necrotizing bronchitis and diffuse alveolar damage, which may manifest as consolidation (17).

The most typical CT features of COVID-19 pneumonia are bilateral multifocal ground-glass opacities; compared to other viruses, the lesions have more frequently a peripheral location, involve the five lobes, and are associated with peribronchovascular thickening (18). In all cases of severe viral pneumonia complicating in ARDS, an evolution from a ground-glass to a consolidation pattern can be observed. Moreover, bacterial coinfections can further complicate the picture concurring to consolidation pattern. Compared to influenza viruses, a lower frequency of bacterial coinfection has been reported in COVID-19, especially in the early phases of hospitalization (19). Of note, pulmonary embolism is highly prevalent in COVID-19 compared to other infectious agents, especially in critically ill patients (20). In case of a clinical-radiological discordance or respiratory worsening, a CT scan with contrast medium injection is useful to diagnose pulmonary embolism (18).

Hematological and biochemical tests may be of help in the correct definition of the clinical framework, contributing to the identification of injury to other organs, to the prognostic stratification of affected patients, and to the monitoring of the disease course (9). Unfortunately, there are no specific peripheral blood diagnostic findings, since viral pneumonia may result in elevated, normal, or decreased white blood cell counts (21). However, viral etiology is less commonly associated with elevated white blood cell counts than bacterial pneumonia. In the case of SARS-CoV-2 infection, for example, lymphopenia (often associated with eosinophylopenia and piastrinopenia) has been correlated with more severe outcomes (22). A correlated marker is the neutrophil/lymphocyte ratio (NLR) which, although not specific, is often increased in severe forms of viral pneumonia and was recently proposed as an early risk stratification marker also for COVID-19 patients (23).

As a reactive phase reactant, the C-reactive protein (CRP) level may be elevated with viral pneumonia, although this is neither a specific nor a sensitive finding (9, 24). In the case of SARS-CoV-2, an early increase of CRP beyond 15 mg/liter correlates with disease severity (25), whereas values higher than 200 mg/liter at admission are a strong predictor of a higher risk of death (26). The detection of procalcitonin (PCT) is less sensitive and even less specific in the case of viral respiratory infection, since its amounts are heavily affected by the parallel secretion of virus-elicited gamma interferon (IFN-γ) (21). Its main role in the course of a viral infection may be to monitor for possible secondary bacterial superinfections (27, 28). Nonetheless, different meta-analyses evidenced the association between higher PCT levels and a significantly increased risk of severe clinical forms of COVID-19 (29, 30).

As an acute-phase protein, ferritin is known to be affected by the inflammatory state (31). Its increasing levels have been proposed as a marker of adverse outcomes in SARS-CoV-2-infected patients (32).
Finally, arterial blood gas parameters (i.e., pO₂, pCO₂, pH, lactate, and bicarbonate) are obviously of pivotal importance in the continuous monitoring of patients with pneumonia (33).

**THE RESPIRATORY VIRUSES AND THEIR DIRECT MECHANISMS OF TISSUE DAMAGE**

Lung involvement may be the effect of both direct and indirect virus-induced mechanisms of tissue damage. These mechanisms are often dramatically different when considering RNA and DNA viruses (Fig. 1).

**RNA Viruses**

Orthomyxoviruses. Influenza viruses are responsible for seasonal epidemics and those of type A (influenza A viruses [IAV]) can cause sporadic pandemics. Most influenza cases are caused by self-limiting viral infections typically limited to the upper respiratory tract. However, mainly for IAV, infected patients may evolve possible
complications ranging from secondary bacterial infections to primary viral pneumonia and bronchiolitis (34).

Influenza viruses may infect a variety of cells within the respiratory tract, including ciliated epithelial cells, type I and II alveolar cells, and immune cells. The final effect on infected cells is dependent on the specific cell type. Virus tropism is due to the capability of influenza viruses to bind different isoforms of sialic acid present on host cells. As an example, the higher pathogenicity of some influenza subtypes (i.e., the “avian” H5N1) may also be related to their higher affinity for the sialyl-galactosyl residues linked by 2-3-linkage [Neu5Ac(2-3)Gal] present in the deeper respiratory tract, thus leading to a more severe lung involvement (35).

Even if it is evident the cytopathic effect of influenza viruses in vitro, it is important to evidence the role played by the innate immune response in contributing to massive cell damage during influenza infection. As already evident from the description of cases observed during the 1918 influenza pandemic, the lung damage in the case of primary viral pneumonia is mostly due to the overproduction of inflammatory cytokines that, however, is potently triggered by virus replication in lung cells, type II pneumocytes, alveolar macrophages or, in certain cases, the activation of endothelial cells (36, 37). In this context, both activated macrophages and infected dendritic cells (DCs) further trigger a massive immune response and the cytokine storming (38, 39).

In general, RNA viruses are good inducers of cytokine production; additionally, influenza viruses are peculiar RNA viruses since they replicate their fragmented genomes within the host cell nucleus. Consequently, a description of the main molecular steps involved in virus replication is essential for a better comprehension of influenza pathogenesis at the cellular level. The replicative cycle of influenza viruses starts with the engagement of sialic acid by hemagglutinin (HA), which triggers clathrin-mediated endocytosis into the host cell. The acidification of the endosome triggers both the HA-mediated fusion process and the release of the viral ribonucleocapsids thanks to the M2 ion channel, which allows acidification of viral core responsible for the release of the viral ribonucleoprotein (vRNP) complexes from M1 protein. The vRNP are now free to migrate into the cell nucleus by using the importin-α/ importin-β nuclear import pathway (40, 41). After the entry into the nucleus, all genomic segments are then transcribed (two of them are spliced by host cell machinery), capped and polyadenylated by the RNA-dependent RNA polymerase for the cytoplasmic phase of virus protein synthesis. In parallel, the RNA-dependent RNA polymerase complex binds to leader sequence of encapsidated RNA fragments and synthesizes whole complementary antigenomes, which will be further used as a template for the formation of novel RNA genomic segments (42, 43). The viral enzyme passes over the transcription signal of all RNA segments during the genome replication phase. Both structural and nonstructural proteins composing the virus ribonucleocomplexes produced in the cytoplasm reenter the nucleus and assembly. A high level of influenza M1 protein stimulates the nuclear export protein-mediated transfer of neosynthesized virus genome segments back into the cytoplasm (43). The nuclear export of vRNP represents another crucial step for productive infection in lung cells, and it is also dependent on the viral-induced increase of reactive oxygen species (ROS) in the infected cell (44).

The path of neosynthesized envelope virus glycoproteins (HA and neuraminidase [NA]) is different from that of the other influenza proteins. They are synthesized into the cell cytoplasm but do not need to go back into the nucleus. IAV viral envelope proteins are synthesized by endoplasmic reticulum (ER) ribosomes, as well as cellular secretory proteins. Neuraminidase (NA), HA, and M2 are cotranslationally directed to the ER thanks to the interaction of viral hydrophobic targeting sequences with the signal recognition particle. HAS of most IAV infecting humans are endowed with a monobasic cleavage site required for HA activation; this site can be cleaved by different proteases present in human epithelial cells in the airways such as the transmembrane protease serine S-1 member 2 (TMPRSS2) and the human airway trypsin-like protease (HAT). HAT is present at the plasma membrane level, and it can cleave both new synthesized
HAs and HA present in cell-associated virions (43, 45–51). TMRPS2 is also present in the trans-Golgi network; at this level it cleaves HA traveling to the plasma cell membrane. Importantly, the TMRPS2 expression seems to be higher in the upper and lower respiratory tracts; in contrast, the HAT is mainly represented the upper respiratory tract, suggesting an important role for TMRPS2 in pulmonary infection (52).

During the assembly phase, the ribonucleocapsids interact with HA and NA and, following M2-mediated membrane depolarization, the viral budding starts, followed by NA-mediated viral release (53). These latest phases directly affect both viral shedding and the clinical evolution of influenza, as demonstrated by NA inhibitors, which are capable of improving flu symptoms only when used in the early phases of infection (54).

During this replicative cycle, the host cell defense machinery is not just a passive bystander, and intracellular innate sensors such as cellular RIG-like receptors (RLR) can recognize the virus and activate the so-called “antiviral state.” In this way, RIG-I recognizes viral RNA and triggers an intracellular signaling cascade, leading to the production of cytokines. Meanwhile, the virus tries to counteract the cellular sensing by blocking RIG-I through its NS1 protein (55). However, these counterstrategies cannot block the production of interferons since Toll-like receptors (TLRs) are also involved in virus recognition (56). Therefore, upon sensing of interferons, host cells are able to transcribe IFN-stimulated genes (ISGs) directly involved in the antiviral state (57).

The activation of these genes is associated with possible viral clearance but may also dramatically contribute to cell damage and clinical severity, especially when the lower airways are involved. Several cellular antiviral defense mechanisms, such as the production of ISGs and mediators altering cholesterol cell homeostasis or cell endocytic pathways, elicited by influenza replication have been described (58–63).

It is evident that influenza-derived cell damage is largely due to a severe deregulation of cell homeostasis even if, in vitro cytopathic effects due to the virus are evident in different cell types. The final effect is highly dependent on the specific cell type infected. In vivo, influenza virus-infected cells are generally cleared via apoptosis and by both innate and adaptive immune response (64, 65). Interestingly, it has been shown that specific populations of epithelial pulmonary cells, named club cells, are able to survive to viral infection thanks to a strong IFN response (66, 67). Moreover, it has been experimentally demonstrated that, after surviving the infection, these cells can acquire an improved antiviral response phenotype possibly required for a nonspecific antiviral immunity after IAV infection, suggesting a tuning of the innate immune response following IAV infection (68).

In fact, even if influenza virus is cytopathic, some cells can also reduce virus replication surviving to the infection. It has been speculated that these “survivor cells” may play an important role in driving the tissue inflammation by altering host response to secondary bacterial infections. Moreover, they could function also as a “long-term” source of viral proteins for the antigen-presenting cells (APCs) (66, 69).

**Paramyxoviruses.** The Paramyxoviridae family comprises several viruses involved in human infections, divided into two subfamilies: the Paramyxovirinae and the Pneumovirinae. The former includes parainfluenza viruses (belonging to the Respirovirus and Rubulavirus genera), measles virus, and mumps virus (Morbillivirus) among others; the latter includes respiratory syncytial virus (RSV) and human metapneumovirus (belonging to the genera Pneumovirus and Metapneumovirus, respectively) (70).

Most infections caused by paramyxoviruses are limited to the upper respiratory tract, but the lower respiratory tract may also be involved in specific settings (i.e., RSV bronchiolitis in newborns and pneumonia in children younger than 1 year of age) (71). All paramyxoviruses share several structural analogies: they have a single-stranded nonsegmented RNA genome of negative polarity, they have an envelope, and some of them (Respirovirus and Rubulavirus) have HA and NA on the same spike.

As discussed more fully below, paramyxoviruses bind to different receptors. The docking with cellular receptors is followed by the fusion of virus envelope with host cell plasma membrane that precede ribonucleocapsid release in the cytoplasm. After
transcription, viral mRNAs are capped and polyadenylated within the cytoplasm, and replication is supposed to start when an adequate nucleoprotein cytoplasmic amount guarantees the encapsidation of neosynthesized genomes. The virus transcriptase complex, formed by the large protein (L) and phosphoprotein (P), produces new genomes from a double-stranded RNA replicative intermediate. The viral ribonucleocapsid (RNP) is then composed of the association of the transcriptase complex and the nucleocapsid protein (NP) linked to the new genomes. RNP then interacts with the matrix viral protein under the plasma membrane and buds from the infected cell via the ESCRT complex, releasing new virions (72, 73).

Paramyxoviruses have shown to be very efficient in counteracting the mechanisms of innate cell immunity. Many of them encode an immune evasion protein, the V protein, which interferes with RNA recognition in the cytoplasm thus blocking IFN production and induction of the antiviral state (74). V proteins are also known for their ability to interfere with STAT proteins to prevent ISG expression. These proteins also interact with RIG-I-like receptors (RLRs) (75, 76). In particular, inhibition of MDA5 seems to be extremely important to further prevent signaling involved in antiviral effectors production (77, 78).

As anticipated, the tropism of different paramyxoviruses is dependent on their cell receptor usage, and in vitro they can infect a broad variety of cells (79). Respiroviruses and some rubulaviruses can use sialoglycoproteins or glycolipids (80). Interestingly, wild-type clinical isolates of measles virus (WT-MV) cannot use the CD46 receptor as laboratory strains can do. Instead, both lab strains and WT-MV can recognize Signaling Lymphocytic Activation Molecule Family member 1 (SLAMF1) and nectin 4. SLAMF1 can be found on a variety of cells such as activated T, B, and dendritic cells and monocytes (81). Nectin-4 is present on polarized epithelial cells present also in the respiratory tract. The usage of this receptor is important for proper replication of MV also in the upper airways from which the virus can be shed through aerosol. When cultured in vitro, paramyxoviruses cause a lytic infection, although they can also lead to the formation of inclusion bodies and syncytia. The latter represent an important immune-escape strategy allowing the virus to hide from the immune system. Paramyxovirus transmission is mainly airborne. Most infections start and end in the upper respiratory tract, as in the case of most infections caused by human parainfluenza virus 1 (HPIV-1). Sometimes, especially for measles virus (MV), the infection may spread to other sites such as lymphoid or endothelial tissues, while RSV can infect both type I and II pneumocytes (82). The parotid gland, central nervous system (CNS), and endothelial tissues are sites of replication for mumps virus (MuV) (83), whereas Hendra virus (HeV) and Nipah virus (NiV) may target the lungs and CNS (84).

Coronaviruses. The Coronaviridae is a large family comprising viruses able to infect a broad range of avian and mammal species and includes seven species of human interest: HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1 are endemic and cause seasonal infections; MERS-CoV and SARS-CoV are epidemic viruses; and SARS-CoV-2 is responsible for the current COVID-19 pandemic (85–91). Endemic coronaviruses (CoV) mainly cause self-limiting infections restricted to the upper respiratory tract, although severe manifestations (e.g., pneumonia and bronchiolitis) can happen with higher frequency in young, elderly, and immunocompromised patients. Conversely, epidemic and pandemic viruses frequently replicate in the lower respiratory tracts and are associated with higher lethality rates.

CoVs possess the largest (ca. 27 to 32 kb) monopartite, positive-strand RNA genome of all viruses infecting vertebrates. The genome architecture is conserved and presents the nonstructural proteins (nsp) at the 5’ region and the structural proteins S, E, M, and N at the 3’ region. Furthermore, several species-specific accessory proteins are interspersed among the structural genes and relevantly affect CoV pathogenicity (92). The viral particles are formed by a ribonucleocapsid (viral genome and protein N) with helical symmetry surrounded by an envelope decorated by the S, M, and E proteins and several host proteins, including kinases, cyclophilin A, and APOBEC3G, that can
either promote or hamper viral replication (93, 94). Furthermore, HcoV-HKU1 and HcoV-OC43 also expose an HA-esterase that facilitates both viral entry and release (95–97).

All CoVs share the same replicative cycle, that is started by the interaction between protein S and a specific host receptor. Different CoV species, even those belonging to the same lineage, can recognize different receptors or have marked preferentiality to the same receptor of different hosts (98). Also, host receptors can be either proteinaceous or glucidic.

Protein S is a prototypical class I viral fusion protein and thus requires at least one proteolytic cleavage to separate the receptorial (S1) and fusogenic (S2) subunits and mediate fusion (99). Cleavage can happen during biogenesis (usually catalyzed by furin in the Golgi apparatus), upon attachment (catalyzed by membrane proteases such as TMPRSS2), or at the endosomal level (catalyzed by cathepsins). It has been documented that variations in the cleavage sites can alter cellular tropism (100, 101). Once protein S is engaged by host receptors and properly cleaved, it can mediate fusion either at the plasma membrane or in the late endosomes, and the CoV genome is released in the cytoplasm.

CoV genomic RNA (gRNA) is polyadenylated and possesses a 5’-cap synthesized by a viral machinery composed of nsp10, nsp13, nsp14, and nsp16. Therefore, the 5’ portion of the genome, containing a single open reading frame (ORF1ab), can be readily translated. It encodes two polyproteins alternatively translated by ribosomal frameshifting that contain all nsp’s. Mature proteins are released by proteolysis from two viral proteases, the papain-like domains of the multifunctional nsp3 and the chymotrypsin-like protease nsp5 (102, 103).

Once mature, most of the nsp’s participate in the formation of the replication-transcription complex (RTC) that localizes in the double-membrane vesicles (DMV), organelles formed by the virus-induced remodeling of the ER and Golgi apparatus (104, 105). DMVs serve to gather the viral proteins and nucleic acids in order to optimize replication and protect the latter from the host innate immune response. CoV nsp3, nsp4, and nsp6, all possessing transmembrane domains, are implicated in DMV formation and are thought to tether the RTCs to the membranes. Once formed, the RTC begins the synthesis of CoV negative-strand RNAs that can be either continuous or discontinuous, respectively, generating the template for the gRNA replication and subgenomic RNAs (sgRNAs) transcription. Each structural and accessory gene is preceded by a conserved body transcription-regulatory sequence (TRS) and a leader TRS is present in the 5’ untranslated region (UTR). During negative-strand production, every time a TRS complementary is synthesized, the replicative machinery can either proceed or translocate to the leader TRS, producing negative-strand sgRNAs of different lengths, all presenting the 5’-UTR sequence (106). The transcription of negative sgRNAs will produce 5’-capped and polyadenylated mRNAs of different lengths in which the structural or accessory gene at the 5’ will be translated. In the cytoplasm, sgRNAs are translated, and the structural proteins S, M, and E are delivered to the ER, while gRNAs are encapsidated by protein N. The concerted action of proteins N, M, and E leads to virion budding into the ER-Golgi intermediate compartment (ERGIC) and their subsequent release by exocytosis (107).

CoV replication is generally associated with a delayed and dramatically reduced IFN induction in most cell types. The capacity of evading the innate immune response seems to be the highest for SARS-CoV-2, followed by SARS-CoV and MERS-CoV and, generally, human endemic CoVs are worse inhibitors than epidemic and pandemic viruses (108, 109). In the case of SARS-CoV, this leads to the dysregulated activation of inflammatory monocyte-macrophage response, in turn causing vascular leakage and impaired B- and T-cell activation (110). Furthermore, IFN response, particularly of type I, may have either positive or detrimental effect depending on the moment and context in which it is induced (111).

The two main physical factors involved in a dampened infection sensing and IFN induction are the association of viral RNAs with protein N and the protective role of DMVs (112). Recently, SARS-CoV-2 nsp3 has been shown to form pores that allows the passage of
molecules from the DMVs lumen to the cytoplasm. Of note, the authors speculate that negative-strand RNAs remain confined in the DMVs and that only mature positive-strand sgRNAs and gRNAs migrate to the cytoplasm. This suggests a selective segregation in the DMVs of single- and double-strand RNA intermediates that are more susceptible to recognition from the host innate response, thus dampening IFN induction (113). Also, CoV RNAs are further protected by complexation with protein N when in the cytoplasm.

Nonetheless, CoV infection is still sensed by the host innate immune response, since viral RNAs activate PKR, OAS, TLR7, MDA5, and RIG-I, whereas proteins E and M activate NF-κB and TLR-like signaling, respectively (114). Therefore, in addition to the importance of protein N and DMV direct shielding of viral nucleic acids, several CoV proteins are further involved in dampening IFN and ISG induction. Of note, most of the factors have been identified in SARS-CoV, but evidence of analogous function in other human CoVs is often documented. Furthermore, functional conservation in murine CoV-MHV-A59 demonstrates common immune escape strategies among phylogenetically distant species.

The CoV proteins whose inhibitory effect on IFN induction has been characterized so far are nsp1, nsp3, nsp16, protein M, and protein N. More specifically, nsp1 is involved in the downregulation of cellular protein expression by selectively mediating host mRNA degradation and directly blocking its translation (115–118).

The papain-like protease domains of nsp3, besides processing the virus polyproteins, also have deubiquitinase activity on innate immune response factors such as IRF3, IRF7, TBK1, and RIG-I (119).

As previously mentioned, mature CoV RNAs are poor IFN inducers since they are single-stranded, 5′ capped, and polyadenylated. MDA5-mediated IFN production is induced upon CoV infection only in specific cell types. The importance of 5′ capping in downregulation is demonstrated by the increased and generalized IFN production triggered by MDA5 when the 2′-O-methylation activity of nsp16 is abrogated (120, 121). Of note, 2′-O-methylation is the last enzymatic step in viral RNA 5′-capping formation, suggesting a similar, although not directly demonstrated, MDA5 sensing suppression by nsp10, nsp13, and nsp14.

Protein M is also involved in preventing IRF3 function by directly binding to TRAF3 (122–124). The abrogation of the TRAF3-TBK1 complex formation in turn blocks phosphorylation and activation of IRF3.

Finally, protein N is also able to suppress type I IFN induction by directly binding to TRIM25, thus blocking RIG-I ubiquitination. Intriguingly, both SARS-CoV and MERS-CoV protein N are able to inhibit RIG-I-induced IFN production, although with partially different pathways (125, 126). Also, EF1α is another ligand of protein N, and its inhibition leads to several effects on cellular physiology, including protein translation block (127).

Altogether, the suppressive role of nsp’s on IFN induction indicates CoV ancestral evolution to counteract the host innate immune response, and it is therefore conserved in the entire family. In addition, several species- and lineage-specific accessory proteins participate in the process, as demonstrated mainly by epidemic and pandemic viruses. In SARS-CoV, ORF3b has an inhibitory effect on RIG-I, MDA5 and, together with ORF6, the phosphorylation of IRF3 (128). Also, two products of ORF8, -8b, and -8ab, directly interact with IRF3, preventing its dimerization and signaling (129). In MERS-CoV, ORF4a dampens MDA5 signaling through the interaction with PRKRA, downregulates the expression of genes under NF-κB control, and, in concert with ORF4b and ORF5, hampers the nuclear trafficking of IRF3 and activation of the IFNB promoter (130). ORF4b activity also affects IRF3 phosphorylation by abrogating the interaction between MAVS and IκBα. Finally, SARS-CoV ORF9b interacts with PCB2 and E3 ubiquitin ligase AIP4, causing TRAF3, TRAF6, and MAVS selective degradation (131, 132).

A growing body of evidence is highlighting the molecular processes at the basis of SARS-CoV-2 strong immune evasion: SARS-CoV-2 nsp1, nsp6, and ORF3b have greater IFN suppressive activity than do SARS-CoV and MERS-CoV orthologs, and a SARS-CoV-2 ORF3b natural variant identified in two patients with severe disease showed increased IFN suppression (133).
CoVs also show a variable ability to inhibit the expression of ISGs in response to IFN signaling through the activity of several nonstructural and accessory proteins. Specifically, nsp1 and nsp6, respectively, inhibit the phosphorylation of STAT1 and STAT2 in a virus species-specific manner, and SARS-CoV-2 proteins are the strongest inhibitors (134, 135). Other inhibitory proteins commonly involved are M, nsp13, and ORF7b in STAT1 phosphorylation; nsp13, ORF7a, and ORF7b in STAT2 phosphorylation; and ORF6 in STAT1 translocation. It has been reported that SARS-CoV-2 can block STAT1 and STAT2 nuclear translocation, altering the proper induction of ISGs through the interaction of Orf6 encoded protein with Nup98-Rae1 and thus resulting in alteration of the docking of cargo-receptor (karyopherin/importin) complex at the nuclear pore complex (NPC) level (128). Other CoV accessory proteins negatively acting on the expression of genes under the ISRE promoter include MERS-CoV ORF4a and ORF4b, SARS-CoV-2 ORF3a, and SARS-CoV ORF3b (133, 136, 137).

Finally, it has been shown that CoVs are able to reduce antigen presentation, thus downregulating the development of an efficient adaptive immune response. MERS-CoV suppresses HLA expression, while SARS-CoV-2 sensing from the host immune response seems to be repressed by ORF8, which has the unique ability to directly bind to MHC-I at the ER membrane and direct it to the lysosomal compartment (138, 139).

All of these immune evasion strategies are at the basis of the SARS-CoV, MERS-CoV, and SARS-CoV-2 clinical course and pathological features that, although distinct, show remarkable similarities. Severe manifestations are indeed directly mediated by an abnormal immune response that progresses into ARDS through the sustained upregulation of proinflammatory cytokines, the delayed/dampened type I IFN response, and the lack of a switch from the innate to the adaptive immune response. Of note, SARS-CoV-2 also often triggers venous thrombosis, both pulmonary and systemic (140, 141).

A relevant source of differentiation in terms of pathogenesis comes from the receptor that SARS-CoV, MERS-CoV, and SARS-CoV-2 exploit to enter the host cells. MERS-CoV binds to the dipeptidyl peptidase-4 (DPP4), a surface protein mainly expressed on alveolar macrophages and, to a lesser extent, on alveolar epithelial cells and T cells (142, 143). This marked tropism for immune rather than lung cells is at the basis of MERS-CoV immunopathogenesis. SARS-CoV and SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2), which is predominantly found on type II pneumocytes in lungs, although it is also present on several other cell types (innate and adaptive immune cells, vascular smooth muscle cells, cardiomyocytes, and enterocytes) (144, 145). The tropism differences may be at the basis of the lower ability of MERS-CoV to abrogate IFN signaling, since it achieves immune evasion by directly infecting immune cells. A remarkable, receptor-mediated pathogenic process comes from the dysregulation of the renin-angiotensin system (RAS) induced by SARS-CoV and SARS-CoV-2. By binding to ACE2, they induce both its internalization and shedding through ADAM17 activation; a reduced ACE2 activity results in increased vascular permeability, enhanced lung edema, and worsening lung damage and proinflammatory response (146–148). Of note, alteration of ACE2 expression seems to be directly related to the stability of the spike-ACE2 complex, since the endemic virus HcoV-NL63 does not trigger the same RAS alterations, and its spike has lower affinity than SARS-CoV for ACE2 (149, 150). In this scenario, SARS-CoV-2, having the highest affinity for ACE2, may also have the highest RAS-disrupting effect.

While the role of inflammation (and coagulopathy for SARS-CoV-2) has been identified as the main pathogenic player in SARS-CoV, MERS-CoV, and SARS-CoV-2, all of these viruses also have a direct cytopathic effect on infected cells. However, the in vitro effect is highly variable depending on the cell line used for the three viruses and some differences are observed between in vitro and autoptic samples. Of note, viral titer and cytopathic effect are independent, since high yield can be achieved in the absence of direct cell damage. The cytopathic effect is directly related to the induction of syncytia and occurs through the induction of apoptosis and autophagy, while necrosis is less associated with CoV-induced cell death, especially in vitro (151, 152). The role of several
CoV proteins have been identified in the induction of cell death. Protein N has been shown to interact with several host factors, inducing alterations of the cell cycle. Indeed, by interacting with CDK2, CDK4, and CDK6, protein N can arrest the cell cycle in the G1 or S phase and by binding to EF1α it can block protein translation and cytokinesis, leading to cell proliferation inhibition (127). Intriguingly, the comparison of protein N from SARS-CoV and HcoV-229E has shown a direct relationship between the affinity for EF1α and the rate and frequency in which multinucleate cells are induced, thus suggesting a possible pathogenic mechanism that is more pronounced in SARS-CoV. ORF-8b directly induces the autophagosome formation and causes lysosome malfunctions related to ER stress (153). ORF3a directly inserts into the lysosomal membrane and leads to necrosis by promoting caspase-3 activity (154).

DNA Viruses

Adenoviruses. Human adenoviruses (HAdVs) are nonenveloped viruses involved in respiratory disease, such as croup, bronchitis, and pneumonia, as well as ARDS in immunocompromised individuals or patients with preexisting comorbidities (155–159). HAdVs may also cause keratoconjunctivitis, gastroenteritis, or cystitis, and they are preferentially transmitted through respiratory droplets or the fecal-oral route (160). As for other respiratory viruses, adenoviruses may infect respiratory tract also through contaminated hands or fomites (160, 161). HAdVs are included in the genus *Mastadenovirus* in the *Adenoviridae* family. Seven species of HAdVs (A to G) are known; these are further divided into more than 50 serotypes and 70 distinct genotypes (162). The HAdV species most involved in upper or lower respiratory tract infections include HAdV B, HAdV C, and HAdV E (163).

The tissue tropism of each HAdV species determines the different clinical manifestations and is driven by the different host cell receptors recognized. However, receptor usage is not the only element driving tissue tropism. As an example, genotypes Ad19 and Ad37, often clinically associated with keratoconjunctivitis, bind to α2,3-sialic acid or CD46 that are broadly expressed in vivo on other, different cell types (164). HAdV C and E recognize the CXADR (coxsackievirus and adenovirus receptor) (165), which is a component of the epithelial apical junction complex also behaving as a cell adhesion molecule important for tight-junction integrity. This receptor is usually expressed in lung, pancreas, brain, heart, small intestine, testis, and prostate and, at a lower level, in liver. Also, it is possibly involved in transepithelial passage of leukocytes (166, 167). CD80, which acts as a cell receptor for HAdV B, is expressed in the tonsil, lymph node, vermillion appendix, gastrocnemius, liver, upper lobe of the lungs, and other tissues, and CD86 is expressed in the tonsil, monocyte, leukocyte, granulocyte, mononuclear cell, lymph node, and vermillion appendix (168).

The adenoviral protein involved in host cell receptor attachment is the fiber glycoprotein mediating the endocytosis and fiber shedding (169). Endosomal acidic pH triggers the release of viral capsid in the cell cytoplasm thanks to the viral protein VI activating membrane repair system, leading to the production of plasma membrane ceramides which promote virus penetration into the endosomal membrane. It has also been suggested that virus entry can be enhanced by elevated levels of autophagy (155, 164). Then, after release, the virus penetrates into the host cell nucleus for replication. Early genes (E) are first transcribed by host RNA polymerase II, and replication of the virus genome by DNA strand displacement occurs. Late genes (L), coding for structural proteins, are then transcribed by the host cell RNA polymerase II, and new virions are assembled into the nucleus. Viral progeny is then released by cell lysis through autophagy and autophagy-mediated caspase activity (170). The lytic infection caused by adenovirus infection probably represents the most typical example of virus direct damage to the host cells. However, as already seen for other viruses, the cell sensing of viral compounds heavily alters the physiology of infected cells starting from the early phases of viral replication. It has been reported that the initial innate immune response to adenoviruses in alveolar macrophages induces pathways that regulate the epithelial polarity of host cell receptors (polarization of CAR and αV integrins involved in virus
docking on the apical surfaces of respiratory epithelial cells) by inducing the secretion of interleukin-8 (IL-8) (171). It has also been observed that membrane damage during adenovirus cell entry triggers a cell stress response (172, 173). Further signaling pathways are activated by the presence of virus DNA and the expression of virus-associated small RNAs (174).

Adenoviruses evolved several strategies to counteract cell sensing and cell mechanisms hampering virus intracellular trafficking in different cell types. As for other intracellular pathogens, the adenovirus E3 protein interacts with host immune system elements for immune evasion (175, 176). Moreover, host cell pathways connecting E3 to proinflammatory NF-κB signaling in respiratory epithelial cells were also described. In particular, there are findings suggesting that E3-RIDα regulates NF-κB activity (155, 177). AdV infection affecting the bronchial and bronchiolar mucosa or the pulmonary alveolus (both type I and II pneumocytes are permissive to virus infection) can cause necrotizing infection. Zaki and Paddock described how, in tissue sections, distinct intranuclear basophilic inclusions, surrounded by a small halo or often filling the entire nucleus, may be appreciated (178). The inclusion bodies, composed of adenovirus viral particles within the cell nucleus, were also detected by electron microscopy (179).

Herpesviruses. The Herpesviridae family comprises human viruses highly prevalent in the global population, the most relevant being herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and varicella-zoster virus (VZV). These viruses all share the ability, upon primary infection, to establish lifelong latency in specific cell types that can lead to reactivations with variable frequency. Primary infections and reactivations are defined as lytic, characterized by the expression of most open reading frame (ORFs) and the production of viral progeny. Conversely, during latency, only a small subset of genes, generally named latency-associated transcripts (LATs), is expressed and necessary to maintain the virus genome as an episome in the nucleus (180). The viral particles carry a large, linear dsDNA genome presenting 100 to 200 ORFs, depending on the species. The genome is surrounded by an icosahedral capsid, a complex tegument, and an envelope decorated by an unusually high number of viral glycoproteins. The general features of the Herpesviridae replicative cycle are conserved, and it takes place as follows. The entry phase is mediated by a cascade of interactions among surface glycoproteins, where a minimal functional unit can be identified in a receptorial protein (gD, following HSV naming), an activator (the gH/gL complex), and a fusion protein (gB). Whether the fusion events happen directly at the plasma membrane or in the endosomes depends on the virus species and the host cell types (181).

Once released in the cytoplasm, the nucleocapsid is shuttled to the cell nucleus, where the genome is replicated and transcribed. The ORFs expressed during the lytic phase can be divided according to their temporal expression into three groups: immediate-early, early, and late genes. Immediate-early genes are involved in the protection from the host innate immune response and have a regulatory effect on the transcription of the early genes that encode the replicative machinery. Late genes are translated into the structural proteins necessary to produce the viral progeny (182, 183). The newly formed nucleocapsids are assembled into the nucleus and released by exocytosis after two subsequent budding events from the inner lamella nuclear membrane and the Golgi apparatus (184).

The immune system of healthy individuals can limit the lytic phase; indeed, viral glycoproteins and nucleic acids are recognized as pathogen-associated molecular patterns (PAMPs), thus activating the innate immune response and inducing IFN signaling. Furthermore, viral replication stimulates the host cell stress responses. However, all Herpesviridae members have evolved a plethora of effectors capable of downregulating the sensing and signaling pathways involved in IFN induction, the expression and effect of ISGs, and dysregulating the cell death programs induced by ER stress and DNA damage response (185, 186). Dampening the IFN response allows the herpesviruses to efficiently enter the latency phase following primary infection, whereas modulation of the cell death program is cell type specific and therefore has a multifaceted
role. Indeed, herpesviruses are often able to induce apoptosis in immune cells, further promoting evasion, and in cell types where the lytic phase takes place, but can protect from apoptosis those where they enter latency. Two notable examples are HSV and VZV, which are able to induce and block apoptosis in epithelial cells and neurons, respectively (187). Consequently, viral proteins involved in these processes are timely expressed: regulators of the IFN response and promoters of programmed cell death are encoded by immediate-early genes and therefore are readily produced during the lytic phase. Several effectors are also part of the tegument; thus, their role is exerted as soon as the envelope fuses to the cell membranes during entry. Conversely, effectors blocking the apoptotic pathways often are LATs (188, 189).

None of the *Herpesviridae* family members primarily target the lungs; nonetheless, several of them can cause interstitial pneumonia, bronchopneumonia, and ARDS in specific settings. Specifically, VZV, CMV, EBV, and HSV are associated with nosocomial primary infections and reactivations in ICU patients (190). CMV is also among the most common opportunistic pathogens causing pneumonia in transplanted patients, especially those undergoing hematopoietic cell transplant, HIV-infected patients, and newborns. The latter group is also afflicted by primary perinatal HSV infections, which are characterized by systemic dissemination and have a worse outcome when associated with pneumonia. In general, a fully functional immune response can control the lytic phase of herpesviruses, impede their dissemination, and drive the progression to latency and then maintain it. Conversely, lung involvement is a variably frequent consequence of herpesvirus systemic spread associated with immune deficiencies, particularly those associated with a T-cell response. A notable exception is VZV community-acquired pneumonia, a severe complication associated with primary infection in immunocompetent adults.

Pulmonary involvement can be a consequence of different pathological processes, depending on the *Herpesviridae* species. HSV pneumonia is mainly caused by HSV type 1 and affects immunocompromised patients and immunocompetent adults subjected to prolonged intubation. Pulmonary manifestations range from necrotizing tracheobronchitis to necrotizing and interstitial pneumonia and are usually caused by HSV orolabial reactivation that progresses into tracheal or lung infection (191). HSV can be found in both type I and type II pneumocytes, epithelial cells, and leukocytes. Infection causes the formation of inclusion bodies and syncytia that results in a marked infiltration of inflammatory cells in the lung parenchyma, necrosis, and alveolar hemorrhage (192). Neonatal infections are mainly due to HSV type 2 infections acquired during delivery predominantly from acutely infected women. Lung involvement is part of a disseminated, multiorgan infection that happens in approximately 25% of neonatal HSV infections and represent the most severe complication (193).

CMV pneumonia can happen both in newborns and immunocompromised adults. Similar to HSV infections, lung involvement in the two categories is radically different. Neonatal CMV pneumonia is preferentially caused by infection acquired during delivery or perinatally, and it is usually caused by direct, descending airway infection, as suggested by a significantly lower lung involvement in congenital infections (194). Conversely, lung involvement in immunocompromised adults is secondary to systemic spread either following primary infection or reactivation. Finally, rare CMV pneumonia has also been reported in immunocompetent individuals (195). Regardless of the immunological state of the patient, CMV pneumonia is often characterized by intermittent symptoms due to recurring immune responses associated with diffuse interstitial infiltrate. The typical CMV cytopathic effect, characterized by intracytoplasmic and intranuclear inclusion bodies, can be identified in type I and type II pneumocytes, alveolar macrophages, and mesenchymal cells, showing CMV broad tropism (196).

VZV is the only *Herpesviridae* member characterized by a significant prevalence of pneumonia in immunocompetent adults, albeit an impaired cellular immune response favors the pulmonary involvement (197). Pneumonia pathogenesis is caused by a defective control of primary infection that, upon systemic dissemination, reaches the
lungs. Rarely, recurrent pulmonary involvement is also associated with VZV reactivation in immunocompromised patients. VZV lung infection rapidly progresses, showing the clinical signs of interstitial pneumonia and ARDS and often leading to death by untreatable hypoxemia (198). Histopathological characterization shows scattered hemorrhagic focal necrosis characterized by the presence of inclusion bodies in infected type I and type II pneumocytes. Of note, VZV shows tropism for monocytes, leukocytes, and dendritic cells, all infiltrating the lung parenchyma, and can deregulate their functionality (199, 200). This feature, although not fully understood, is at the basis of VZV dissemination to the lungs independently from the immune competency of the infected individual.

**Human bocaviruses.** Human bocaviruses (HBoVs) are single-stranded DNA (ssDNA) genome naked virus members of the *Parvoviridae* family. They have been described in respiratory samples from patients with respiratory illness or gastrointestinal clinical symptoms and may be transmitted via the respiratory route, or by ingestion, reaching the gastrointestinal tract (201). HBoV1 was first reported in patients with infections of the lower respiratory tract (202), and it was suggested that it might be associated with acute expiratory wheezing and pneumonia (203–205), whereas other bocaviruses are more related with diarrhea (206). It is estimated that up to 19% children under 2 years old with acute respiratory illness worldwide carry HBoV1 genome, and 10 to 20% of nasopharyngeal aspirates from hospitalized children with lower respiratory illness are also positive for HBoV1 (203, 207–210). Respiratory diseases correlated with the presence of HBoV are usually mild and often characterized by the presence of other respiratory viruses (204, 211–214). Severe respiratory infections, including life-threatening acute bronchiolitis and pneumonia, linked to HBoV1 have also been reported (205, 212, 215–218).

From the few data generated in *vitro* and the homologies with human parvovirus B19, the proposed replication model for HBoV suggests (216) a first docking with host cell receptors (sialic acid and heparan sulfate) triggering clathrin-mediated endocytosis (219). After permeabilization of the endosome membrane, the virion enters the nucleus via microtubular transport. At the nuclear level, the double-stranded viral DNA is synthesized by host cell enzymes. Viral mRNAs are then transcribed when host cell enters the S phase; alternative splicing of messengers allows expression of eight different mRNAs and then translation occurs. The viral VP2 is translated by “leaky scanning” of the gene encoding VP1, and VP3 is generated via VP2 cleavage (220). Nonstructural virus proteins contribute to genome replication which would occur by a rolling-hairpin mechanism. Then, the NS1 endonuclease, recognizing the 5’ ends of the viral genomes, contributes to the excision of neosynthesized ssDNA genomes thanks to a process known as junction resolution. At this stage of viral replication, the novel ssDNA can both function as a template for transcription and be encapsidated into new virions that can be then released by lysis of the host cell (221).

The pathogenetic mechanisms of HBoV1 have not yet been elucidated due to the lack of animal models and of cell lines allowing a fine and reproducible characterization of its replicative cycle. It has been shown that HBoV1 can replicate in human embryonic kidney HEK293 cells after transfection with an HBoV1 clone and produces progeny virions (222). Even more importantly, it was also shown that HBoV1 can infect polarized differentiated human airway epithelium (HAE) cell preparations on both apical and basolateral surfaces. This evidence suggests that HBoV1 can induce tissue damage at the airway epithelial level by possible alteration of ciliary function, alteration of cell-cell junctions, or through the induction of epithelial cell hypertrophy (223–227).

**IMMUNE-MEDIATED DAMAGE INDUCED BY RESPIRATORY VIRUSES**

As already anticipated in the previous section, the role of the immune system during a viral infection is balanced on a thin line between protection and exacerbation of virus-induced damage (Fig. 2).
Protective Role of Immune System against Respiratory Viruses

The immune system is equipped with pattern recognition receptors (PRRs) that are involved in viral sensing by recognizing PAMPs unique to viruses and other microbes. For viruses, their genetic material acts as PAMPs, which are detected by the host PRRs.
when viruses enter or replicate in a cell or, as viral replication intermediates from dying cells.

The receptors critical for recognizing viruses are (i) Toll-like receptors (TLRs) such as TLR3 (double-stranded RNA), TLR7/8 (single-stranded RNA), and TLR9 ( unmethylated CpG DNA) which signal in a TRIF-dependent manner; (ii) retinoic acid-inducible gene (RIG-I)-like receptors (RLRs), including RIG-I, and melanoma differentiation-associated protein 5 (MDA5) that detect cytosolic, single-stranded, or double-stranded viral RNAs of various lengths to initiate IFN signaling; (iii) nucleotide-binding oligomerization domain (NOD)-like receptors (NLR), such as NLRP3, that recognize RNA viruses and cellular perturbations to activate ASC/Caspase-1-dependent inflammasomes; and (iv) cytosolic DNA virus sensors such as RNA Pol III (converts viral DNA to RNA for detection by RIG-I), AIM2, IFI16, and cGAS/STING that activate inflammasomes or IFNs. These receptors are expressed in the respiratory epithelial cells, as well as in the tissue-resident immune cells. Upon viral sensing, the PRRs activate signaling pathways that trigger the release of type I and III IFNs, as well as proinflammatory mediators, including cytokines, chemokines, and antimicrobial peptides, that assist in the prevention and clearance of respiratory viral infections.

**Prevention of respiratory infections.** The respiratory tract is continuously exposed to the external environment that increases the likelihood of encountering pathogens. The lower and upper airways are uniquely fortified for detecting and eliminating external threats to maintain homeostasis and prevent infections. The lung epithelium and endothelium associated with resident immune cells actively survey for foreign threats while after viral encounter, immune cells such as neutrophils, monocytes, dendritic cells (DCs), T cells are recruited to resolve the infection.

**(i) Airway epithelium.** The respiratory epithelium consists of ciliated columnar epithelial cells associated with nonciliated airway basal cells and secretory cells (serous, neuroendocrine, goblet, and club cells), which secrete mucus, enzymes, proteases, and antimicrobial peptides. It starts as the nasal epithelium continuing onto the trachea to the bronchus and bronchioles and finally forming the alveolar epithelium (made up of AT-I and AT-II cells).

Cell-cell junctions among epithelial cells, including apically located tight junctions, the underlying adherens junctions, gap junctions, and desmosomes, provide an impermeable structure resistant to infections. In the pseudostratified columnar epithelium, they maintain basal-to-apical directionality by the Na⁺, K⁺, and Cl⁻ ion gradient that guides secretion and enables intercellular communication and transport (228, 229). In some cases, despite apoptosis of ciliated cells, the lung barrier functions were retained during H1N1 and H3N2 IAV infections by maintaining transepithelial resistance and expression of tight-junction proteins (230). Others reported that H1N1 and H5N1 IAV infection damaged the epithelial cell tight junctions affecting the epithelial-endothelial barrier and was dependent on the loss of a tight-junction protein, claudin-4 (231). Inflammatory responses during RSV infections destabilizes cell-cell junctions by decreased expression or cleavage of tight-junction proteins such as occludin and claudin-1 and enhanced claudin-2 expression that increases barrier permeability (232, 233).

The mucus layer formed by mucins secreted by the goblet cells protects the epithelium by forming a physical barrier against an incoming virus and limiting access to the lung surface. Several isoforms of mucins are present in the lungs that are either secreted (MUC5B, MUC5AC, and MUC2) or are bound to the epithelium (MUC4, MUC13, MUC16, and MUC21). In addition to its barrier function, in an IAV infection, the secreted MUC5AC isoform acts as decoy for sialic acid receptors (the receptor for IAV binding) and thus limits exposure of the epithelium to IAV (234). Another study showed that the mucin layer senses viruses such as herpes simplex virus (HSV) and facilitates an early release of CXCL10 and recruitment of neutrophils prior to even IFN responses (235).

Lipids and surfactant proteins (released by the epithelial cells) in the alveolar space contribute to the structure and function of pulmonary surfactant and have antiviral functions. AT-II epithelial cells constitutively secrete the surfactant proteins SP-A, SP-B,
SP-C, and SP-D. SP-B and SP-C reduce the surface tension in the alveoli to withstand the dynamic changes during ventilation but have limited antiviral properties. SP-A and SP-D, described in detail below, function as “collectins” or soluble PRRs that sense several viruses and microbes and enhance opsonization by alveolar macrophages and neutrophils.

Upon viral encounter, the pulmonary epithelium secretes several cytokines, chemokines, and antimicrobial peptides (AMPs). Cytokines (e.g., TNF-α, IL-6, IL-1β, G-CSF, and GM-CSF) broadly regulate immune responses, as well as cell proliferation and maturation, and control viral spread (described in detail below). Chemokines produced by the lung epithelial cells stimulate the recruitment of neutrophils, T cells, NK cells, DCs, monocytes, and granulocytes to the lungs. In addition, the lung epithelial cells also produce peptides such as β-defensins, lactoferrin, and nitric oxide (NO), which have antiviral activity (described in detail below). Secretory leukocyte protease inhibitor in the lungs has little antiviral abilities but protects the lung tissue integrity from harmful proteolytic enzymes released by the epithelial and inflammatory immune cells.

The airway epithelial cells also maintain homeostasis by regulating the inflammatory state in the lungs. For example, the cells prevent aberrant IL-1β responses by secreting IL-1RA and IL-1RII inhibitors in the steady state. However, during viral infection in the lungs, the anti-inflammatory state can be rapidly reversed by the release of other proinflammatory cytokines.

(ii) Endothelial cells. Pulmonary endothelium is a dynamic layer of squamous cells on the surface of the lung vasculature and is a critical regulator of vascular homeostasis. At steady state, the endothelial cells have antiplatelet, anticoagulant, and fibrinolytic properties and maintain vascular integrity. Upon microbial infections, the endothelium expresses cytokines, chemokines, adhesion molecules, and growth factors.

While the airway epithelia are the primary target of respiratory viruses, viruses such as RSV that also directly infect the lung vascular endothelium cause respiratory distress and extensive tissue damage due to proximity to the alveoli, as well as increased permeability of inflammatory mediators, leading to pulmonary edema. Endothelium damage affecting vascular permeability and fluid leakage can also be indirectly mediated by leukocyte-driven inflammation and damage to the alveolar epithelium.

During infections, microvascular endothelial cells secrete macrophage inflammatory protein 1β (MIP-1β) and MIP-2 (CXCL2) or IL-8 that recruit neutrophils into the inflamed lungs. The activated endothelium also produces the proinflammatory cytokines, chemokines and interferons (e.g., IL-6, TNF-α, IL-1β, CCL2, CXCL9, CXCL10, and type I and II IFN) (236, 237), and adhesion molecules (e.g., PECAM [CD-31], ICAM–1, VCAM, and E selectin) that recruit leukocytes to the site of infection and mediate leukocyte/endothelial-cell adhesion.

(iii) Alveolar macrophages. Lung-resident macrophages are present within the alveolar airspaces to protect the lower airways from external pathogens, and they make up >90% of the leukocytes. Alveolar macrophages are highly phagocytic and ingest all types of inhaled, inert particulates in the alveolar spaces such as amorphous silicates, carbon-graphite particles, without triggering inflammation. In healthy lungs, a homeostatic microenvironment is sustained by maintaining the macrophages in an immunosuppressed state by the alveolar epithium through surfactant release, nitric oxide, IL-10, TGF-β, or GM-CSF signaling (238, 239). The alveolar macrophages also maintain a state of T-cell inactivation by decreased expression of costimulatory molecules (240) or through expression of CD80 that binds the negative T-cell receptor, CTLA-4 (241).

Upon viral infection of the lower respiratory tract, the microenvironment rapidly changes into an inflammatory state that removes the suppressive stimuli to activate the alveolar macrophages that initiate host immune response and viral clearance. Upon resolution of the infection, the acute inflammatory state in the lungs is reversed by efferocytosis, a process by which the inflammatory cells containing cytotoxic mediators are removed. After influenza virus infection, efferocytosis is primarily driven by the alveolar macrophages that remain in the alveolar space after the inflammation is
resolved (242). Lipid mediators such as lipoxins, protectins, and resolvins produced by the alveolar macrophages also potentiate efferocytosis (243). Alveolar macrophages return to their original quiescent state by producing TGF-\(\beta\) and IL-10.

Alveolar macrophages are essential in the lungs during viral infections such as RSV infections, where they mediate early antiviral responses by cytokines and IFN secretion. However, during several other respiratory viral infections, namely, IAV and coronavirus infections, the alveolar macrophages are often depleted from the lungs. In fact, in COVID-19 patients, the severity of the disease correlates with the reduction in tissue-resident alveolar macrophages, along with the accumulation of the inflammatory, monocyte-derived macrophages (244).

(iv) Neutrophils. Neutrophils (245, 246) are the first immune cells to migrate to the lungs during respiratory virus infections and are crucial for removing infected and dying cells. Neutrophils phagocytose viral particles and apoptotic bodies from dying cells that contain viral particles and replication intermediates. Neutrophils release intracellular and extracellular granules containing cytotoxic enzymes, AMP, and ROS (produced by NADPH oxidase) to inactivate or eliminate the viral pathogens. Activated neutrophils also form and release NETs (neutrophil extracellular traps) composed of decondensed chromatin and histones that biophysically incapacitate viruses and avert viral spread. In addition, activated neutrophils also modulate other innate and adaptive immune responses by secreting chemokines that recruit more neutrophils, activate T-cell responses through IFN-\(\gamma\)-secretion and antigen presentation, or hone B-cell activity. Efficient neutrophil recruitment and activity check disease pathogenesis in respiratory viral infections. Generally, the activated, inflammatory neutrophils at the sites of infections are short-lived as they undergo apoptosis or NETosis (i.e., programmed cell death accompanied by formation of NETs, which are cleared by tissue-resident macrophages). However, unmitigated neutrophil-mediated activity (e.g., release of ROS, myeloperoxidase, proteolytic enzymes, chemokines, and NETs) in the alveolar space impaired neutrophil cell death or inefficient clearance of dying cells by alveolar macrophages causes hyperinflammation and acute tissue injury.

(v) Dendritic cells. The lung-resident DCs consist of CD103\(^+\) or CD11b\(^+\) conventional DCs (cDCs) and plasmacytoid DCs (pDCs). The cDCs are of two types: (i) CD103\(^+\), CD8\(\alpha\)\(^+\), IRF8\(^+\) type I (or cDC1) and (ii) CD11b\(^+\), CD8\(\alpha\)\(^+\), IRF4\(^+\) type II (or cDC2). In the steady state, CD103\(^+\) cDC1 cells remain associated with the lung epithelium and are the primary antigen-presenting cells (APCs) that are responsible for activating both CD8\(^+\) and CD4\(^+\) naive and memory T cells upon antigen encounter. Upon infection, CD103\(^+\) cDCs are the first to migrate to the draining lymph nodes (dLN) to elicit CD8\(^+\) T-cell-dependent protective immunity. Deficiency in CD103\(^+\) DCs during influenza leads to a reduced cytotoxic-T-cell (CTL) population in the lungs and severe pulmonary inflammation (247). CD11b\(^+\) DCs arrive in the dLN later during the infection, and this augments the expansion of effector lymphocytes and the secretion of proinflammatory cytokines. Both cDC populations drive Th1 activation and promote effective memory responses against subsequent infections (248–251).

During homeostasis, cDC1 cells have a greater capacity to present antigens to CD8\(^+\) T cells, while cDC2 cells are more efficient in activating CD4\(^+\) T cells (252–254). During viral infections such as influenza, some groups showed that cDC1 cells are responsible for inducing CD8\(^+\) T-cell responses (255, 256), while others claimed that cDC2 cells are more important (257, 258). Recently, through single-cell analysis, it was demonstrated that during respiratory virus infection, cDC2 cells acquire properties similar to cDC1 cells and monocyte-derived cells (such as the expression of IRF8 and CD64, respectively) to become efficient APCs that induce CD8\(^+\) and CD4\(^+\) T cells simultaneously. These inflammatory CCR2-expressing cDC2 cells, induced by type I IFN, were distinct from the monocyte-derived cell population, which were unable to function as effectively as APCs (259).

pDCs are also associated with viral sensing, initiating immune responses, and producing large amounts of type I IFN and human \(\beta\)-defensins. Although pDCs can
transport viral particles to the dLN, they are poor inducers of naive T-cell responses due to low expression of costimulatory molecules (250, 251). pDCs function differently in respiratory viral infections depending on the viral pathogen. For example, pDCs are dispensable for IAV sensing and clearance. However, during RSV infection, pDCs promote viral clearance and modulate inflammation to reduce lung injury (260).

(vi) Monocyte-derived DCs. Monocyte-derived DCs (moDCs) and macrophages differentiate from monocytes that migrate into the lungs during infection. The inflammatory monocytes are involved in Th1 differentiation, cytotoxic effector responses, and activation of naive and memory CD8+ T cells and NK cells that expedite efficient viral clearance (250, 261). Type I IFN and chemokines (e.g., CXCL10 and CCL2) produced by moDCs further expand inflammatory responses and increase inflammatory monocyte recruitment to the sites of infection. In fact, increased numbers of CCR2+ inflammatory monocytes or moDCs producing elevated levels of NO and TNF-α during viral infections display greater mortality and morbidity in mice. However, complete depletion of moDCs favored uncontrolled viral dissemination and disease severity. Interestingly, a partial attenuation of inflammatory monocytes in the lungs reduced inflammation-driven lung damage but did not affect viral clearance. These observations allude to the requirement of a fine balance in monocyte numbers and functions in the lungs that benefits the host in controlling respiratory viral infections without pulmonary tissue damage.

(vii) Tissue-resident lymphocytes. The relatively abundant and diverse population of tissue-resident lymphocytes in the lungs synergizes with the early myeloid responses during respiratory infections to launch an efficient innate immune response before activation of the antigen-specific T-cell responses. Innate lymphoid cells (ILCs), including natural killer (NK) cells, and the “unconventional” T cells, including invariant NKT (iNKT) cells, γδ T cells, and mucosa-associated invariant T (MAIT) cells, constitute the innate tissue-resident lymphocytes (262, 263).

ILCs are a heterogeneous population of cells expressing a variety of genetically coded activating and inhibitory receptors, which are found at epithelial barriers and can initiate rapid immune responses upon infection or injury (262). ILCs can be further differentiated into subgroups based on differential expression of the transcription factors, cell surface receptors, and cytokines produced. Group 1 ILC consists of type 1 ILCs (ILC1s) and mature NK cells, which express the transcription factor Tbx21 (T-bet). However, they differ in their abilities to produce IFN-γ in response to IL-12 and IL-18. Furthermore, ILC1 are primarily tissue-resident cells, whereas NK cells remain in circulation and are recruited in response to chemokines. ILC1s mount an early antiviral response at the local sites of viral infection through IFN-γ production prior to the other tissue-resident lymphocytes. NK cells respond to the viral infection within a few days after neutrophil activation to produce IFN-γ; initiate cytotoxic killing of infected cells, and trigger more specific adaptive immune responses. NK cells eliminate infected cells by releasing cytotoxic granules containing granzymes and perforin, activating death receptors, or through antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit viral dissemination. NK cells also enhance CTL activity through IFN-γ production. In IAV infection, the virus evades NK cell-mediated killing by inhibitory receptor signaling. Some influenza virus strains infect NK cells, albeit ineffectively, to induce apoptosis, thus limiting NK cell-dependent cytotoxicity. In RSV infection, IFN-γ production by NK cells may cause tissue damage. However, in IAV infection, NK cells have been shown to produce IL-22 and initiate tissue regeneration.

ILC2s are characterized by Th2 cytokines, IL-4, IL-5, and IL-13, which are secreted in response to IL-25, TSLP, and IL-33 produced in the lungs (262) and are primarily implicated in tissue repair after resolution of infection. ILC2s initiate repair by producing amphiregulin (similar to CD4+ T cells) mediated by IL-33 produced by epithelial cells. Furthermore, IL-5 produced by ILC2s, following the clearance of IAV infection, also leads to the accumulation of new eosinophils in the lungs (264). Interestingly, ILC2s are regulated by type I and type II IFNs, which are produced early in a viral infection and
can inhibit ILC2 activity in a STAT1-dependent manner (265, 266). ILC3s are distinguished by their expression of retinoid-related orphan receptor γt (RORγt) transcription factor and production of IL-17A and IL-22 in infections (262). ILC3s are implicated in tissue repair responses. Functions of ILC3s have been primarily described in the gut but may also limit airway hyperreactivity during respiratory infections via IL-22 secretion (267). However, similar to ILC2s, the beneficial repair functions of ILC3s can be directly blocked by excess type I IFN signaling during viral infections.

"Unconventional" T cells are defined by their limited T-cell receptor diversity, their ability to recognize antigens without MHC-I or MHC-II presentation, and their swift effector responses that also activate downstream T-cell-mediated adaptive immunity (268). Type 1 (or iNKT) and type 2 NKT cells are differentiated on the basis of their TCRα chain repertoire. iNKT cells are a significant cell population in respiratory viral infections; they produce the inflammatory cytokines IFN-γ, IL-4, IL-17, and TNF-α, they mount antigen-specific cytotoxicity, and they activate innate and adaptive immune responses through APCs to protect against infections (268). Endogenous self-derived lipids (presented by MHC-I like molecule [CD1d]) and cytokines produced during viral infections activate iNKT protective functions. In influenza, iNKT cells were necessary and sufficient for host survival and resolution of infection through the regulation of myeloid-derived suppressor cells and confirmed by correlative data in human influenza (269). iNKT cells were also implicated in CD8+ T-cell activation and expansion in RSV clearance (270).

γδ T cells express the less-diverse γδ TCR (compared to the αβ chains in conventional T cells) that are present in mucosal barrier surfaces and are activated by different multiple microbial pathogens to establish inflammatory responses, as well as regulate tissue homeostasis and repair (271). In patients that survived the 2003 SARS infection, the expansion of memory γδ T-cell population that produced IFN-γ and mediated cytotoxic cell death of SARS-CoV-infected cells may have directly contributed to survival (272).

MAIT cells respond to a diverse range of microbial metabolites from bacterium-infected cells and yeasts via their reactivity to MHC-I like protein, MR1, but do not directly sense viral molecules. However, MAIT cells respond to IL-12 and IL-18 to produce IFN-γ, TNF-α, and IL-17 that augment other antiviral immune responses (273, 274). The observations were corroborated in MR1-deficient mice lacking a MAIT cell population that showed greater weight loss and increased mortality during lethal H1N1 influenza infection (275). However, MAIT cell activation reinforcing an inflammatory response during viral infections has been associated with both protective and pathological functions. It is not yet clear whether MAIT cell activities also correlate with hyperinflammation during severe influenza infections (276).

(viii) B cells and T cells. The adaptive immune system working through antibodies, B cells and T cells are ultimately responsible for absolute viral clearance and memory formation. B cells produce specific neutralizing antibodies that opsonize and inactivate virions, as well as eliminate virus-infected cells. Neutralizing antibodies encase viral particles to diminish their infectivity and promote phagocytosis by neutrophils and macrophages. The antibodies also bind to viral proteins expressed on the surfaces of infected cells and activate complement-mediated ADCC. Due to its rapid and effective role in viral clearance, antibody-mediated protection is often a coveted outcome of several vaccination strategies. In fact, the presence of neutralizing antibodies against rhinovirus and influenza virus in the blood, prior to infection, correlates strongly with disease protection (277). Neutralizing antibodies can also cross-react and confer extensive protection against a wide variety of viruses. For example, it was recently discovered that neutralizing IgG from plasma of COVID-19 patients recognizes a common epitope that recurs in the spike proteins of SARS-CoV2, SARS, and MERS of the coronavirus family (278). However, as presented for SARS previously (279), while completely protective, an antibody response to COVID-19 may be relatively short-lived (280, 281) compared to a usual cell-mediated immune response.
CD4⁺ follicular helper T cells (Tfh) are important for launching an effective B-cell response in infections through the formation of germinal centers in secondary lymphoid tissues (required for B-cell maturation, proliferation, and memory). Increased Tfh cell numbers have been associated with high vaccination-induced, influenza-specific IgM and IgG antibodies (282). Adoptively transferred CD4⁺ T cells in mice lacking mature T cells promote an effective antibody response to protect from an IAV infection, but not in SCID mice lacking both T cells and B cells. Depletion of CD4⁺ T cells also correlated with decreased antibody responses during SARS infection (249). Athymic mice that do not express mature, functional T cells are unable to clear virus and succumb to IAV infection. CD8⁺ T cells are essential in the highly pathogenic SARS infections, and adoptive transfer of SARS-activated T cells into SCID mice promotes survival and reduced viral loads (283). A study analyzing the blood of critical COVID-19 patients identified SARS-CoV2 spike glycoprotein-specific CD4⁺ T cells in 100% of the patients, whereas 80% of the patients had specific CD8⁺ T cells, which appeared early in the infections and were enhanced over time (284).

Lungs also harbor resident CD103⁺ CD8⁺ T cells, also referred to as tissue-resident memory T cells (TRM), which provide cross-protection against different strains of influenza virus, as well as against coronaviruses (284). The antiviral cytotoxic functions of TRM cells are fortified by infiltrating CD8⁺ effector T cells (Teff). The TRM cells undergo rapid proliferation and activation upon reinfection or cross-reaction with a different strain of virus, which are enhanced by an increase in Teff cells in the lungs. However, with increasing intervals between exposure to cross-reacting viruses, TRM cells are usually replaced by CD103⁻ CD8⁺ central memory T cells that exhibit a delayed kinetic and more inflammatory phenotype in the lungs (285).

Clearance of viral respiratory infections. Cytokines, chemokines, and other factors released from epithelial and immune cells in response to respiratory viral infections are central to launching appropriate antiviral responses that limit viral replication and dissemination. However, dysregulation of the protective antiviral pathways by highly pathogenic viruses triggers severe immunopathology that undermines host fitness and causes tissue injury. The initial antiviral cytokines produced in response to viruses are the IFNs and IFN-stimulated genes (ISGs), followed closely by proinflammatory cytokines such as IL-1, IL-6, and TNF-α. The chemokines are responsible for leukocyte migration to the sites of infections and localized release of antiviral cytokines and effectors. Other secreted effectors include β-defensins, NO, and surfactant proteins that function as antimicrobial agents.

(i) Interferons and antiviral ISGs. Type I and type III IFNs are the primary antivirals that are produced upon viral sensing, which in turn activate numerous ISGs capable of interfering with viral replication and spread and are responsible for critical and effective antiviral host responses. In fact, disease severity in the current COVID-19 pandemic has been linked to genetic deficiencies in IFN or the presence of anti-IFN autoantibodies (286, 287).

Type I IFN (including IFN-α and IFN-β) bind to the ubiquitously expressed IFN-α/β receptor (IFNAR). Meanwhile, type III IFNs (IFN-λ1 or IL-29; IFN-λ2/3 or IL-28A/B) bind to a heterodimer consisting of IL-10Rβ and IFNLR (IL-28R), with the latter being expressed specifically on mucosal epithelium, dendritic cells, and neutrophils. Both IFNs activate JAK/STAT and IRF9 to induce a largely overlapping set of antiviral ISGs. Almost all nucleated cells secrete type I IFNs and IFN-λ are secreted by epithelial cells or cDCs in the lungs, depending on the virus and site of infection. In viral infections, the initial upsurge of type I IFN, followed by IFN-λ, is crucial for removal of virions and infected cells and thus negatively regulates immune cells involved in tissue repair and regeneration to augment apoptosis and inhibit epithelial cell proliferation. Unlike type I and type III IFNs, type II IFN (IFN-γ) does not have direct antiviral effects but promotes adaptive immune responses upon activation by T cells, iNKT cells, NK cells, or ILCs.

During viral infections, human airway epithelial cells produce more IFN-λ than type I IFN. Recent studies have shown that of the two IFNs, type III IFN is more predominant...
in the airway epithelium (228, 229) and potentially less damaging. In mice, during poly(I·C) stimulation (to mimic RNA virus), IFN-λ is produced primarily by cDC1 cells, while type I IFN is produced by epithelial cells, alveolar macrophages, and moDCs. Furthermore, type I IFN production peaks early upon poly(I·C) stimulation or IAV infection, while IFN-λ production is less potent but sustains longer over the duration of infection. Both type I and type III IFNs have nonredundant and coordinated critical roles in controlling susceptibility and viral clearance in influenza infection, as observed in Ifnar<sup>−/−</sup> or Ifnlr1<sup>−/−</sup> mice, and the effects were more pronounced in IFNAR and IFNLR1 doubly deficient mice (288–290). In SARS-CoV-2 infection, disease severity correlated with an early, elevated, and persisting type I IFN signature in the blood and bronchoalveolar fluids, whereas the type III IFN levels increased late and were sustained. Type I IFN responses are associated with effective viral clearance but cause severe immunopathology (288). Comparatively, the initial IFN-λ-induced antiviral state at the mucosal surfaces is less detrimental to the host (291) and is also critical for control of virus dissemination in the upper airways (292).

Autocrine and paracrine IFN responses initiate a cascade of specialized, antiviral ISG expression that is involved in the (i) inhibition of viral entry (e.g., MX1, IFTIM, and TRIM proteins), (ii) prevention of viral release (e.g., Viperin), (iii) apoptosis of infected cells (e.g., PKR), and (iv) regulation of transcriptional and posttranscriptional protein synthesis and posttranslational processes (e.g., Viperin and ISG15). Several ISGs activated downstream of IFN signaling also participate in the innate and adaptive immune systems by triggering recruitment (chemokines), antigen presentation, and the release of other cytokines.

(ii) Chemokines. Chemokines produced in respiratory infections by the airway epithelium stimulate the migration and recruitment of immune cells responsible for viral clearance. Excess chemokine production leads to excessive leukocyte infiltration and subsequent hyperinflammation and tissue damage. Neutrophil recruitment, survival, and degranulation during viral infection require IL-8 (CXCL8) signaling. Dysregulation of IL-8 causes excess release of neutrophil proteases and ROS, leading to lung tissue damage and ARDS (293). An ISG, IP-10 (CXCL10), mediates the recruitment and activation different types of leukocytes. CXCL10/CCR3 protects against respiratory viruses such as RSV (294), whereas excess signaling during IAV infection caused tissue damage through uncontrolled immune cell-mediated inflammation (295, 296). CCL2 (MCP-1) is a mediator for monocyte recruitment and plays a dual role in respiratory viral infections. A heightened monocyte induction by CCL2/CCR2 signaling in viral infection adversely affects lung pathology (297, 298). However, CCR2-deficient mice also had better outcomes but with delayed clearance of IAV virus (299, 300). In addition, diminished CCL2 expression correlated with the deletion of an immune regulatory factor, A20, in the lung epithelium, which resulted in a better prognosis in late stages of IAV infection (301). CCL5 (RANTES) is an ISG that mediates the chemotaxis and activation of T cells, NK cells, monocytes, DCs, and granulocytes and provides protection against viral infections in the lungs. CCL5 responses favored survival in IAV-infected mice (302) but aggravated inflammation and airway hypersensitivity in response to RSV infection (303).

(iii) Inflammatory cytokines. In addition to IFN responses, proinflammatory cytokines are produced in the lungs during respiratory viral infections; these cytokines include IL-6, TNF-α, and IL-1, as well as granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). IL-6 controls the transition to adaptive immune responses by regulating the recruitment, differentiation, and activation of monocytes and T cells, as well as by downregulating neutrophil activity (304). H1N1 IAV infection in Il6r<sup>−/−</sup> mice underlined the importance of IL-6 in virus-induced neutrophil cell death that negatively affected viral clearance, lung damage, and mortality (305, 306). IL-6 is also critical in viral clearance during subsequent infections by recalling memory CD4<sup>+</sup> T cells by inactivating Tregs (307). While high levels in the lungs correlate with disease severity, IL-6 is instrumental in the control of virus replication and spread (308). Similarly, elevated levels of lung TNF-α is associated with
severe immunopathology but is required for inhibiting viral replication, enhancing cytotoxicity in infected cells, and cytokine production in leukocytes (308).

Another proinflammatory cytokine, IL-1β, is produced rapidly by the activation of the NLRP3 and/or AIM2 inflammasome upon viral recognition. IL-1β is required for survival during viral infections and augments neutrophil recruitment and CD8⁺ T-cell activation but also adversely affects lung inflammation (309–311). IL-18 maturation is also regulated by the NLRP3 inflammasome. During influenza infection, IL-18 potentiates cytokine production from activated CD8⁺ T cells and enhances the cytotoxicity of NK cells (312). However, IL-18 functions can be double-edged, since other studies have shown that IL-18 deficiency can provide protection against viral dissemination (313). Like most other proinflammatory cytokines, a fine balance in IL-18 levels and activity is required which decides whether the cytokine is beneficial or detrimental to the host.

G-CSF and GM-CSF are differentiation factors for myeloid lineage cells. G-CSF regulates the neutrophils by enhancing their differentiation, expansion, and survival (314, 315). GM-CSF promotes the proliferation and activation of lung DCs and macrophages to aid in an effective T-cell response and pathogen clearance. The lungs of GM-CSF-deficient mice are highly vulnerable to viral infections but can be rescued by the exogenous administration of GM-CSF (316, 317).

(iv) Other antiviral factors. The airway epithelium secretes several antimicrobial peptides, enzymes, protease inhibitors, and oxidants that directly inhibit the respiratory pathogens and/or regulate immune responses. Lactoferrin, β-defensins, cathelicidins, and NO are produced in the alveolar space and interfere with respiratory viral infections.

Lactoferrin is a glycoprotein that inhibits infection by directly binding to both DNA and RNA viruses, as well as by blocking the host receptors required for viral entry (318). β-Defensins are cationic peptides that neutralize viruses by forming a pore-like structure on the pathogen membrane and causing efflux of essential nutrients and ions. β-Defensin 1 (BD1) is constitutively expressed, whereas BD2, -3, and -4 expression is induced upon infection (e.g., IAV) (319). β-Defensins also induce cytokine production by epithelial cells and facilitate the migration of immature DCs and memory T cells (320). Cathelicidins (LL37) are released by epithelial cells and via neutrophil granules (321). The antiviral properties of LL37 include disrupting the viral envelopes and enhancing immune cell recruitment and inflammatory responses (322). The exogenous administration of LL37 lowered the mortality, morbidity, and viral titer in mice infected with IAV (323). Nitric oxide (NO) is constitutively produced by the respiratory epithelia and is further induced by respiratory viruses and proinflammatory cytokines (324). NO and other reactive nitrogen species (RNS) inhibit viral proteins and processes such as replication and transcription. However, RNS activity, like ROS activity, can be indiscriminate and modify host protein functions as well as cause lung injury (324).

As mentioned previously, the highly conserved, hydrophilic surfactant proteins SP-A and SP-D or “collectins” secreted by AT-II epithelial cells have antiviral properties by which the proteins detect viruses in the alveolar space and facilitate their clearance by phagocytes (325). The C-terminal lectin-type domains of SP-A and SP-D act as PRRs that bind with various affinities to complex carbohydrates or associated toxins found on the surfaces of respiratory viruses and other pathogens (326, 327). In IAV infection, SP-A competitively binds viral HA protein through its α-(2,3)-linked sialic acid motifs and thereby blocks viral entry (331, 332). SP-D binds to and promotes the aggregation of HA proteins on IAV to disrupt the optimal functioning of the virus. SP-D-deficient mice with IAV infections had reduced virus clearance and hyperinflammation in the lungs, which is directly dependent on the PRR capabilities of the protein, and independent of its surfactant properties (333). Interestingly, in humans, gene polymorphisms affecting the expression of SP-A, -B, and -D correlated with severe influenza disease (334, 335).

The respiratory epithelium and endothelium, along with lung-resident immune cells, are actively involved in preventing viral infections in the airways. During a viral
onslaught, a rapid influx of inflammatory cells occurs that aims to prevent, contain, and clear the infection. The clearance of virions and virus-infected cells, as well as blocking viral dissemination, is greatly reliant on the antiviral cytokines and chemokines secreted by the infected epithelia and activated immune cells at the sites of infection. Cellular infiltration and activation during an infection is a double-edged sword since the protective functions can become damaging to the host unless controlled. Although viruses have evolved with the hosts to evade and manipulate host immune responses, the entry of activated immune cells and the release of cytotoxic, antiviral factors in infected lungs are strictly regulated by the airway epithelium and tissue-resident cells.

**Role of Immune System in Lung Damage**

Immune responses, including the migration of leukocytes and the release of cytokines and chemokines, are critical for viral clearance and a return to homeostasis but often are also responsible for disease complications and tissue injury that may compromise host fitness during disease, as well as in the long term. Dysregulation of the immune responses directly by viruses or as a result of a persisting infection has far-reaching pathological consequences. Such immunopathological effects arise from (i) increased infiltration of inflammatory cells, (ii) enhanced cellular activity resulting in elevated levels of secreted cytokines and chemokines, and/or (iii) erroneous feedback regulation. Here, we will focus on the roles of cytokines, especially the newly highlighted roles of IFNs, in propagating lung damage. The relevance of neutrophils and T cells in lung immunopathology has been described previously and extensively (328–330).

Uncontrolled inflammation during respiratory viral infections or “cytokine storm” is responsible for extensive lung injury and severe immunopathology. A cytokine storm (also known as the “cytokine release syndrome”) is an excessive immune response caused by interplay between immune cells and cytokines such as TNF-α, IL-6, IL-1, IL-12, IFN-α/β, IFN-γ, MCP-1, and IL-8 and is characterized by systemic elevation in the levels of the cytokines and chemokines (336). Infections with several respiratory viruses—such as IAV, RSV, SARS-CoV, and SARS-CoV-2—cause the dysregulated infiltration of neutrophils and inflammatory monocytes and increased cytokine production that destabilize tissue integrity (337). Neutrophils, inflammatory macrophages, and other hyperactivated immune cells can further propagate structural tissue damage by producing cytotoxic free radicals, reactive nitrogen and oxygen species, proteases, and profibrotic mediators that modify and damage the pulmonary epithelium. Sex may also be an underlying factor dictating cytokine responses and clinical outcomes during respiratory viral infections. In COVID-19 patients, males had higher IL-8 and CCL5 in blood, whereas higher TNFSF10 and IL-15 levels correlated with worse outcomes in females. While both males and females had increased monocyte populations, males had more nonclassical monocytes in circulation. In addition, CD8⁺ T-cell responses were more robust in females rather than in males (338).

Several respiratory viruses have been associated with complication in the central nervous system (CNS) (339). Cerebrovascular, neurological, and psychiatric symptoms have been observed in COVID-19 patients, which often leads in ischemic stroke, intracerebral hemorrhage, CNS vasculitis, encephalopathy, encephalitis, and psychosis (340). Loss of smell and taste has also been reported in SARS-CoV-2-infected patients (341–343, 390). Patients with neurological complications have been reported in SARS, MERS, and H1N1 IAV cases during acute infection or correlated with disease severity. Severe RSV-induced bronchiolitis in children is also known to affect the CNS (344–346). The neurological complications occur as a direct result of viral infection or indirectly through the cytokine release syndrome and cell- or antibody-mediated immune responses. Interestingly, a recent study by To et al. showed that SARS-CoV-2 could directly infect neurons in human brain organoids without eliciting type I IFN responses (339).

In influenza, TNF-α is the central proinflammatory cytokine contributing to severe immunopathology. TNF receptor 1 (TNFR1)-deficient mice show unaffected viral spread...
but with lower morbidity during H5N1 IAV infection (391). In addition, in mice lacking both TNF and IL-1 signaling, there was no change in viral clearance but significantly decreased morbidity and mortality (392). IL-1β is beneficial early in IAV infection but leads to disease severity in the later stages of the infection when sustained (311). IL-18 and IL-6 have complicated roles in IAV infection: while they are largely beneficial, increased levels of these cytokines contribute to the “cytokine storm” and are often associated with poor clinical prognosis.

During RSV infections in children, extensive tissue damage is driven by immune cells recruited to sites of infection, which produces the inflammatory cytokines IL-1, IL-6, IL-8, and CCL5 in the upper and lower respiratory tracts. In some patients with severe RSV-induced bronchiolitis, there were several neurological symptoms, such as encephalitis and encephalopathy (346), driven by the induced cytokines. Analysis of cerebrospinal fluid from patients showed augmented IL-6, IL-8, CCL2, and CCL4 levels that correlated with the alterations in the CNS (393).

In COVID-19, the persistent high fever, respiratory distress, and acute lung injury that occur as a result of a hyperactivated immune system are the leading causes of disease complexity. Analyses of the COVID-19 patients from several independent groups unanimously agree upon the detrimental effects of elevated proinflammatory cytokines in driving disease severity and often mortality. An increased level of the inflammatory cytokines IL-1β, IL-18, IL-6, or TNF-α, among others, is a signature of critically ill patients who require hospitalization. Compared to moderate cases, critical COVID-19 patients showed an increased interaction between the pulmonary epithelium and immune cells via receptor-ligand profiling, which was modulated, in part, by heightened chemokine release (e.g., CCL2, CCL3, CCL20, CXCL1, CXCL3, CXCL10, and IL-8) by inflammatory immune cells (394). The SARS-CoV-2 profile shares major similarities with SARS and MERS infections with respect to the proinflammatory cytokines and chemokines found in circulation, which are associated with the coronavirus-mediated “cytokine storm.” However, unlike SARS, SARS-CoV-2 also shows an increased secretion of the anti-inflammatory cytokines IL-4 and IL-10.

The status of the antiviral IFN production in COVID-19 patients is complex; this is compounded by the limited understanding of the newly emerging SARS-CoV-2 virus. Our group observed that type I IFN and IFN-λ2/3 mRNA expressions in the upper respiratory tract of COVID-19 patients were not drastically affected but were greatly enhanced in the bronchoalveolar lavage samples of patients with severe disease (347). Interestingly, tenOever and coworkers reported an attenuated IFN transcriptional profile but high chemokine expression in SARS-Cov-2 infection compared to other respiratory viral infections (348). A larger study by Hadjadj et al. tested 50 patients of different disease severities after 8 to 12 days of initial symptoms and observed a weakened type I IFN signature and ISGs in the blood, which was associated with an increased viral load (349). In contrast, a more recent longitudinal analysis over time led by the Iwasaki group, analyzing a cohort of 113 COVID-19 patients exhibiting either moderate or severe disease, showed a persistent type I and type III signature (350). Elevated levels of both IFN-α and IFN-λ were more sustained in the severely affected patients. However, both studies agreed that IFN-α, and not IFN-β, was the more predominant type I IFN in blood. Moreover, as mentioned earlier, all of these studies observed a similar hyperinflammatory cytokine signature in severely affected COVID-19 patients that eventually drives the pathogenesis, dictates the clinical outcome, and requires therapeutic intervention for disease amelioration.

Unregulated inflammatory cell death provokes excess tissue inflammation and organ failure. Pyroptosis in tissue-resident alveolar macrophages and recruited monocytic macrophages exacerbates lung inflammation by promoting neutrophil infiltration and intense cytokine storm through excess productions of IL-6, TNF-α, and IL-1β (351). IAV infection activates NLRP3 inflammasome in type I IFN- and RIG-I-dependent manner to induce pyroptosis of lung epithelial cells (352–354). Inflammasome and pyroptotic cell death induced by SARS-CoV-2 exacerbates respiratory distress and fever. Acute COVID-19 pathogenesis also affects blood coagulation that often leads to
thrombosis in the lungs (e.g., pulmonary embolism) (355, 356). A recent complication of COVID-19 is the occurrence of pathogen-driven Multi-system Inflammatory Syndrome in Children (MIS-C) that presents as Kawasaki disease (357), and the immunological complications may be mediated by autoantibodies (358).

Secondary bacterial infections or “superinfections” is a quite common clinical complication during an acute respiratory viral infection and is a leading cause of mortality in patients. Viral infections such as IAV infections, and now SARS-CoV-2 infections, make the host more vulnerable to *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, or *Escherichia coli* bacterial coinfections (359, 360). The susceptibility of the virally infected lungs is regulated by multiple factors such as increased damage and delayed regeneration of the airway epithelium, inhibition of antibacterial signaling and cytokines, immune cell exhaustion, and altered activation of pulmonary cells that result in an inappropriate or inadequate immune response or reduced defense capabilities.

The antiviral IFN responses initiated during a respiratory viral infection are of immense importance in virus control and clearance. However, a prolonged exposure to IFNs compromises lung health, drastically increasing host vulnerability to secondary coinfections. It has been demonstrated that *Ifnar*<sup>−/−</sup> mice, which lack type I IFN signaling, could effectively clear a secondary *S. pneumoniae* infection after influenza infection. Coinfection with IAV and *Mycobacterium tuberculosis* also increases the severity of the bacterial disease in a type I IFN-dependent manner (361). In addition, type I IFN can inhibit inflammatory responses by blocking IL-1, inducing IL-10 production (362), and suppressing tissue-resident lymphocytes such as γδ T cells during viral infections (363).

Similar to *Ifnar*<sup>−/−</sup> mice, IFNLR1-deficient mice devoid of IFN-λ signaling are completely protected from *S. aureus* superinfection in a TLR3/TRIF-dependent manner (347). Extended IFN-λ expression in the lung during viral infections induces apoptosis of the infected cells and inhibits the regeneration of the epithelium, leading to a damaged lung barrier and increased permeability. IFN-λ negatively regulates the recovery of the lung epithelium by activating the p53 and/or p21 pathways (347, 364).

Neutrophil-mediated killing is critical for resolving pulmonary bacterial infections. In some cases, such as during nonlethal influenza infection, type I IFN blocks neutrophil recruitment that can favor *S. pneumoniae* bacterial coinfection (363). IFN-λ is also known to negatively impact neutrophil recruitment (365) and their inflammatory functions (366) and thus may be responsible for restricting antibacterial neutrophil activity in the context of a lung superinfection.

In contrast to bacterial superinfections, the role of IFN-λ in fungal coinfections has not yet been established. IFN-λ is known to prime antifungal responses in neutrophils during *Aspergillus fumigatus* infection (367). However, in a fungal coinfection model with chronic IFN-λ exposure, the damage to the lung epithelium is likely to be detrimental as well.

Viral infections often perturb the structure and function of the airways, which can be compounded by the host immune responses. Usually, the resolution of an infection is followed by a return to homeostasis, but in many cases it is dependent on the pathogenic nature of the virus, the extent and spread of the infection, and the degree of the inflammatory response.

Common strains of coronavirus, rhinoviruses, and adenoviruses generally manifest as mild to moderate upper respiratory tract infections in patients without preexisting conditions. In severe cases, these infections present increased leakage and edema, increased epithelial cell death, and hypersecretion of mucus, leading to nasal congestion, sneezing, and coughing. More severe viral infections, such as influenza, COVID-19, SARS, MERS, and RSV infections in children, proceed from the upper to the lower respiratory tracts, where they can spread from the bronchi and bronchioles to the alveoli, if uncontrolled. Cellular changes (e.g., desquamation of epithelial cells and loss of cilia in RSV infection, as well as epithelial cell hyperplasia in IAV infection) and increased
inflammation in the lower respiratory tract drives severe disease pathogenesis due to compromised respiratory functions. Viral bronchitis and bronchiolitis are characterized by restricted airflow and inefficient gas exchange through increased edema and mucus in the lungs, vascular congestion, and tissue swelling. In serious cases, breathing and respiratory functions may be compromised, and patients may require machine support (368). Pneumonia is caused by the viruses that reach the alveoli and destabilize pulmonary functions. In critical cases, fluid build-up in the alveolar space and necrosis, as well as the loss of surface tension and pulmonary elasticity, can lead to ARDS and respiratory failure. ARDS is a clinical hallmark of critical patients with SARS and MERS infections and is emerging to be the same in SARS-CoV-2 infections. ARDS is driven by "cytokine storms" causing extensive inflammation and pulmonary damage, which leads to multiple organ failure, and often death, in cases of severe, high-risk COVID-19 (369).

Viral infections in lungs can cause extensive inflammation-driven damage, but generally, after effective viral clearance, the lung is able to return to its original pulmonary architecture. However, anomalies in the inflammatory or regeneration pathways can adversely affect the structural and cellular makeup of the lungs, leading to fibrosis, emphysema, bronchiectasis, and pneumatoceles.

Acute lower respiratory tract infections directly affect new and preexisting chronic pulmonary diseases. Preexisting chronic obstructive pulmonary disease or asthma are associated with worsening prognoses in patients with pulmonary infections, which manifest as severely irregular inflammatory responses or defects in repair and regeneration. Exposures to different pathogenic microbes and viruses also promote an immunological imbalance in the lungs that increases a predisposition to asthma. Other lung diseases implicated in respiratory infections include tuberculosis, sarcoidosis, hypersensitive pneumonitis, and pulmonary arterial hypertension (370).

Respiratory viruses change the matrix composition of the lungs via collagen and fibronectin deposition that often leads to scar tissue formation. These respiratory viruses effect remodeling through induction of associated factors, angiogenesis and fibroblast proliferation, which is amplified in an atopic environment. Mice infected RSV, followed by allergen challenge, displayed airway remodeling characterized by increased collagen synthesis and thickening of the bronchial basal membrane, which was mediated by RSV-driven fibroblast growth factor 2 (FGF-2) (371). Lung ILC2s primarily have protective functions during infections but can be dysregulated by viruses or sustained type I IFN signaling, resulting in allergic inflammatory responses and exacerbated asthma. Infection with respiratory viruses such as IAV, RSV, and RV can result in ILC2-dependent airway hypersensitivity mediated by IL-33 and TSLP (372–374). Furthermore, IL-33-primed lung ILC2s acquire "memory" that triggers more robust responses upon rechallenge than do unprimed, primary ILC2s (375). Thus, certain respiratory viral infections present an ILC2-dependent allergic immunopathology that affects lung health in the long term.

INVESTIGATIONAL TOOLS TO IMPACT IMMUNE RESPONSES DURING VIRAL INFECTIONS

Multiple clinical studies and therapeutic interventions target the immune responses to mitigate respiratory virus-driven immunopathology. Complementing and reinforcing vaccine discovery, several studies are currently under way to find an effective cure for patients with influenza, RSV, and the newly emerged, highly contagious SARS-CoV-2 infections.

Interventions in respiratory viral infections, including SARS-CoV-2, such as antibody and convalescent plasma therapy, checkpoint inhibitors, alpha-blockers (e.g., prazosin), steroids (e.g., dexamethasone) and, above all, vaccines would require a much more detailed discussion. Here, we report some additional alternative and complementary approaches involving implicated immune pathways and immunomodulatory molecules that are targeted or commissioned for cure and preventive therapies in respiratory viral infections (Fig. 3).
The Possible Therapeutic Role of Interferons

IFNs present an attractive candidate in the treatment of respiratory viral infections due to their well-characterized and pivotal role in virus inhibition and clearance. In fact, many viruses have evolved to bypass or downregulate IFN signaling for a...
successful infection, which underlines the practicality of administering IFNs exoge-

nously to combat viral infections. Type I and type III IFNs also subdue inflammasome

activation and IL-1β expression that contribute to inflammation. Several ongoing clini-
cal trials, worldwide, are assessing the benefits of administering recombinant interfer-
ons in patients at various stages of respiratory viral infections. These efforts have also
multiplied in the recent, novel COVID-19 pandemic to find an effective treatment for
affected people, as well as to formulate IFNs as a preventive measure, while the search
for an effective vaccine is underway.

Type I IFNs are the earliest responders to a viral infection that trigger downstream gene
expression and cellular activation to launch antiviral effector responses. Type I IFN (IFN-α
or IFN-β1) is being tested in clinical trials as an adjuvant to vaccination strategies or as a
treatment and/or prophylactic in respiratory viral infections. Multiple clinical trials have
been initiated to assess IFN-α as in combination therapy (e.g., with oseltamivir) or as a mu-
cosal adjuvant in vaccines to treat and/or prevent influenza infections.

In the light of the recent COVID-19 pandemic, a clinical trial (NCT04320238) is test-
ing the efficacy of IFN-α1β administered nasally in at-risk frontline medical workers
(with thymosin-α, an adjunct used in influenza vaccines, in the high-risk medical staff
working directly with COVID-19 patients) as a preventive intervention. Another clinical
trial (NCT04293887) will use nebulized IFN-α2β to early-diagnosed COVID-19 patients
(within 7 days of onset of symptoms) in combination with other standard therapies
(lopinavir-ritonavir, remdesivir, or antibodies against coronavirus) depending on patient
requirements. Interestingly, a clinical trial (NCT04379518) is assessing the effects a combinatorial therapy of intravenous IFN-α2b (or Roferon A) and rintatolimod
(dsRNA that mimics viral infection) on mild to moderate COVID-19 patients with can-
cer. Clinical trials with another type I IFN, IFN-β1A/B, used standalone or in combina-
tion (NCT04449380, NCT04350671, and NCT04343768) in hospitalized COVID-19
patients are also in progress to treat SARS-CoV-2 infections.

However, type I IFN administration has its limitations since it often presents with
severe side effects in healthy participants that manifest clinically as flu-like symptoms,
fatigue, weight loss, nausea, vomiting, and diarrhea, among others. Type I IFN failed as
an effective antiviral therapy in SARS-CoV 2003 human trials (376) but, based on recent
observations, SARS-CoV-2 is likely to be more sensitive to IFN than its ancestor.

Type III IFN, in contrast to type I IFN, has emerged as a more promising antiviral can-
didate due to its limited proinflammatory effects in the lungs and highly specific sig-
naling repertoire (377). The specific receptor for IFN-λ is restricted to the mucosal epi-
thelium and limited immune cells, such as neutrophils and DCs in humans, but it
shares largely overlapping antiviral functions with the type I IFNs. The specificity of
IFN-λ signaling drastically minimizes the off-target risks and the accompanying toxic-
ity, and it improves tolerability. Pegylated-IFN-λ is an active form of IFN-λ with a longer
half-life, which has been administered successfully for human viral hepatitis treatments
in multiple clinical trials and also exhibited strong antiviral effects against influenza vi-
rus and coronavirus, among others.

A recent study describing a mouse-adapted SARS-CoV-2 showed that peg-IFN-λ1a
can effectively block viral replication in vivo when used early (12 h after infection) or
prophylactically (18 h before exposure to virus) Similarly, pretreatment of human air-
way epithelial cells with peg-IFN-λ1a displayed a dose-dependent decrease in virus
production in vitro (378). Following these observations, several clinical trials are under
way testing IFN-λ as a prophylactic or as early intervention in COVID-19. Clinical trials
testing type III IFN as a treatment (NCT04331899 and NCT04354259) will test mild cases
of COVID-19 outpatients with a single subcutaneous (s.c.) administration of peg-IFN-
λ1a. Moderate cases of COVID-19 requiring hospitalizations are also being tested with
one or two doses of s.c. peg-IFN-λ1a (NCT04354259, NCT04343976, and NCT04388709)
in randomized phase 2 clinical trials. Another randomized Phase 2b clinical trial
(NCT04344600) will estimate the efficacy of peg-IFN-λ1a as a prophylactic in prevent-
ing SARS-CoV-2 in at-risk or asymptomatic participants (e.g., with household exposure
to COVID-19). Eiger Biopharmaceuticals is developing the use of peg-IFN-λ as a mono-
therapy and also with lonafarnib and ritonavir drugs in combination.

However, as we and others have recently demonstrated, timing and duration of type I or
type III IFN treatment is of the utmost importance as continued exposure of the inflamed
pulmonary tissue to IFNs may cause more harm than good in virus-infected lungs (347, 364).
Prolonged exposure to IFN reduces tissue regeneration and escalates host susceptibility to
bacterial superinfections, which is directly related to increased morbidity and mortality in
patients with respiratory viral infections. Moreover, IFN treatment in mice with SARS-CoV
was remedial when applied 6 h postinfection but was unproductive at 12 h postinfection
(110), hence proving further that timing is central to the efficacy of IFN treatment.

The Possible Therapeutic Role of Immunomodulators

As discussed above, protective inflammation during infections induced by the immune
system can become pathological, leading to severe clinical consequences. In respiratory vi-
rnal infections, blocking hyperinflammation (often characterized by "cytokine storms") using
immunomodulators often reinforces the necessary antiviral therapy and has favorable clini-
cal outcomes.

IL-6 is an inflammatory cytokine associated with cytokine storm and ARDS in
COVID-19 patients and other respiratory viral diseases. IL-1β and IL-18 can induce IL-6
and IFN-γ production by lymphocytes, respectively. A high IL-1/IL-6 profile in blood dis-
plays increased neutrophilia and CRP concentrations, whereas a high IL-18/IFN-γ profile
is defined by macrophage activation syndrome (MAS), severe ferritinemia, coagulopathy,
and cytopenia (379). These disease hallmarks are also observed in other inflam-
matory conditions, such as hemophagocytosis lymphohistiocytosis (HLH) and Still’s dis-
ease. Worsening of the disease conditions transforms from a high IL-1/IL-6 signature to
a IL-18/IFN-γ signature in patients, which is similar to what is observed in COVID-19
patients. IL-1 and IL-6 inhibition has been beneficial in Still’s disease, whereas IFN-γ
blockade is effective treating HLH.

Anakinra is an IL-1 signaling inhibitor that is an IL-1RA receptor antagonist and also
hinders IL-18 production. It has been used clinically for over a decade in autoimmune
diseases and Kawasaki disease in infants. Tocilizumab is an IL-6 inhibitor that is effec-
tive in blocking cytokine release syndrome (CRS) and is used to treat rheumatoid arthri-
tis (RA) (380). The timing of administration has not been fully evaluated, considering
an early IL-6 blockade may favor viral dissemination. Using tocilizumab also runs the
risk for contracting secondary infections and may require simultaneous antibiotic treat-
ment. Ruxolitinib and baricitinib are JAK kinase inhibitors that block IFN-γ signaling
through receptor inactivation. Baricitinib is approved to treat RA and can mitigate
chronic inflammation observed in interferonopathies. Inhibition of signaling through
JAK kinase can suppress the detrimental cytokines such as IL-6 and type II IFN, as well
as ameliorate the antiproliferative effects of IFN-λ. However, the broad immunosup-
pressive effects of JAK kinase inhibitors are of paramount consideration when being
employed against viral infections. Infliximab is an approved chimeric monoclonal anti-
body that inhibits TNF-α signaling and is used to treat autoimmune diseases such as
RA and inflammatory bowel disease. Preclinical studies in subjects with viral pneumo-
nia and influenza A showed the protective role of GM-CSF (or Sargramostim/Leukine)
(381, 382). GM-CSF is beneficial to lung health and maturation of alveolar macro-
phages; it activates the immune system to help clear virus, reduces the risk of coinfec-
tions (383), and diminishes morbidity in patients with ARDS (384).

Ongoing clinical trials aiming to reduce "cytokine storm" and restrain intense immu-
nopathology in COVID-19 include the following:

(i) Use of Anakinra alone or with ruxolitinib, as a treatment in acute COVID-19
patients (NCT043666232).

(ii) Anakinra (phase 3) or Emapalumab (phase 2) intravenous (i.v.) administration with
standard care in severely affected COVID-19 inpatients (NCT04324021); Emapalumab is an anti-IFN-γ monoclonal antibody.

(iii) Anakinra or tocilizumab in combination with (in patients with ARDS) or without (in patients with nonhypoxemic pneumonia but no ARDS) ruxolitinib administration in progressed inflammatory COVID-19 disease (NCT04424056).

(iv) A phase 3 clinical trial using one dose of i.v.-administered tocilizumab or siltuximab (anti-IL-6 monoclonal antibody) with or without daily s.c. Anakinra to recover lung homeostasis in ventilated COVID-19 patients (NCT04330638). Currently, a recently completed preliminary clinical trial using Tocilizumab did not show better recovery in COVID-19 patients prompting further studies (NCT04331808) (385).

(v) Comparing IL-6 inhibition in COVID-19 patients with severe pneumonia administered Tocilizumab/RoActemra (i.v. or s.c.) or the anti-IL-6 monoclonal antibody, Sarilumab/Kevzara (s.c.), according to the standard care protocol (NCT04322773).

(vi) Intravenous treatment with Infliximab or Infliximab-abda in phase 2 trials in hospitalized adult COVID-19 patients (NCT04425538).

(vii) XPro1595/Remicade, a second-generation inhibitor that neutralizes soluble inflammatory TNF molecules, will be s.c. administered in COVID-19 patients with breathing complications (NCT04370236).

(viii) Therapy with inhaled (NCT04411680) or vein infusion (NCT04400929) of Sargramostim, or GM-CSF, in acute COVID-19 patients with hypoxic respiratory failure and pneumonia, who need mechanical ventilation.

The Possible Therapeutic Role of Antivirals

Antivirals are drugs that directly target the infecting viruses by interfering with the different stages of a virus life cycle such as viral entry, replication, protein synthesis, and viral particle release. The approved antivirals for influenza include oseltamivir phosphate (Tamiflu), zanamivir (Relenza), peramivir (Rapivab), and baloxavir marboxil (Xofluza). Oseltamivir, zanamivir, and peramivir block the actions of viral neuraminidases (NA proteins) that restrict the movement of virus in the respiratory tract and prevent the release of new viral particles from an infected host cell. Baloxavir, the active hydrolyzed form of Xofluza inhibits influenza virus replication by interfering with the endonuclease activity of the PA subunit of viral polymerase complex. Side effects vary for each medication. The antivirals have some common side effects such as nausea, vomiting, diarrhea, and bronchospasm but are generally considered safe and effective in adults, children, and pregnant women (oseltamivir). Antivirals used to treat severe and high-risk RSV infections include ribavirin (blocks viral polymerase) and palivizumab (monoclonal antibody prevents membrane fusion by binding viral envelope fusion protein). There are no approved antivirals for respiratory adenovirus infections, but the disease can be managed by over-the-counter fever relievers.

During the ongoing COVID-19 pandemic, several other drugs are being repurposed and tested for their efficacies as antivirals.

Remdesivir. Currently, the most-favored, albeit unapproved, drug in the treatment of COVID-19, remdesivir, is an RNA analogue that blocks viral replication in the coronavirus MERS (386). Remdesivir was not successful in the 2015 Ebola virus infections but is used as the current standard care. In the United States, Gilead Sciences received an emergency use authorization for remdesivir treatment in critical COVID-19 patients.

Lopinavir-ritonavir. Lopinavir-ritonavir is an antiviral drug combination used in HIV patients and helps control the infection. They form an HIV protease inhibitor complex that leads to the release of noninfectious, immature viral particles. A trial showed no apparent benefits of lopinavir-ritonavir treatment in COVID-19 patients (387), but several physicians recommended continued use of lopinavir-ritonavir as COVID-19 standard care, considering the relative safety of the drug combination. However, another recent trial at the University of Oxford (RECOVERY trial) that was conducted with a much larger cohort (1,596 treated versus 3,376 control patients) ruled out “any meaningful mortality benefit” of lopinavir-ritonavir use in hospitalized COVID-19 patients.
Hydroxychloroquine. Chloroquine and its less toxic derivative hydroxychloroquine (HCQ) are widely available drugs that have been used to treat malaria and amoebiasis, as well as autoimmune diseases such as RA and systemic lupus erythematosus (SLE). HCQ displayed antiviral properties in vitro, where it inhibited viral entry by altering acidification status of endosome maturation required for membrane fusion and also exhibited anti-inflammatory properties (388). However, multiple, noncontroverted studies found no associated benefits of using HCQ (that outweighs the drastic side effects of HCQ) in hospitalized COVID-19 patients (RECOVERY trial). Recently, U.S. Food and Drug Administration revoked the emergency use authorization for HCQ in the United States.

Colchicine. Colchicine is a safe, affordable, and orally administered anti-inflammatory drug that is currently used for many conditions (e.g., gout, familial Mediterranean fever, and cardiovascular diseases). Colchicine inhibits microtubule polymerization, as well as IL-1-, IL-6-, GM-CSF-, and NLRP3-dependent inflammasome activation. Mindful of the indirect damage caused by inflammatory responses during SARS-CoV-2 infection on multiple organs, including the lungs and heart, a randomized clinical trial theorized that patients receiving colchicine had significantly better clinical deterioration timing (389). Multiple clinical trials are now recruiting to assess the benefits of colchicine for safeguarding against systemic inflammation in COVID-19 patients.

Atovaquone-azithromycin. Azithromycin is a macrolide with antimicrobial properties, including against rhinoviruses, while atovaquone is an antifungal and antiparasitic quinone. This combination therapy is under trials for use in cases of confirmed COVID-19 (NCT04339426).

CONCLUDING REMARKS

Viruses can either exert a direct pathogenic effect on the infected cells or can induce immune-mediated damage. Regarding the latter, both innate and adaptive immunity are involved. A translational understanding of the molecular events leading to lung injury during infections by viral respiratory pathogens has undoubtedly theoretical correlates and practical consequences. A balanced interplay of innate and adaptive immunity is of pivotal importance for viral clearance and memory generation. In fact, cytokines, chemokines, and other factors released since the early phases of virus infection can dramatically limit viral replication and diffusion. However, all viruses evolved counterstrategies capable of hampering both branches of the immune system, thus leading to a dysregulated immune response. Many of the most severe clinical manifestations of respiratory viruses are related to this immune interfering mechanisms. Our comprehension of these mechanisms is increasing, and they should be considered in the future development and clinical use of new immune-based antiviral strategies.

ACKNOWLEDGMENT

We declare there are no competing interests.

REFERENCES


monocytes are a major immunological determinant of severity in previ-
ous healthy adults with life-threatening influenza. JCI Insight 2:e91868.
https://doi.org/10.1172/jci.insight.91868.

chemoattractant protein 1 contributes to an adequate immune response in
1016/j.clim.2007.08.001.

300. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD. 2008. CCR2+ mono-
cyte-derived dendritic cells and exudate macrophages produce infla-
enza-induced pulmonary immune pathology and mortality. J Immunol

Ibañez LI, Hammad H, Lambrecht BN, Beyaert R, Saelens X, van Loo G.
2016. A20 deficiency in lung epithelial cells protects against influenza A
journal.ppat.1005410.

302. Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O

Enhanced viral clearance in interleukin-18 gene-de


306. Huang F-F, Barnes PF, Feng Y, Donis R, Chronou ZC, Idell S, Allen T,
Perez DR, Whitsett JA, Dunusni-Joannoulos K, Shams H. 2013. GS-CSF
in the lung protects against lethal influenza infection. Am J Respir

307. Shibata Y, Berclaz PY, Chronou ZC, Yoshida M, Whisette JA, Trappell BC.
2001. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity

https://doi.org/10.1007/s00018-005-3372-0.

beta-defensins (MBD-1, -2, -3, and -4) in upper and lower airway mucosa of influenza virus infected mice. Virology

https://doi.org/10.1007/s00018-005-3372-0.

https://doi.org/10.1007/s00018-005-3372-0.

bacterial peptide with a role in inflammatory skin disease. Ann Dermatol

313. Barlow PG, Szboda P, Mackellor A, Nash AA, York IA, Pohl J, Davidson,
DJ, Donis RO. 2011. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 6:
e25333. https://doi.org/10.1371/journal.pone.0025333.


L, van Golde LM, van Iwaarden JF. 1995. Interactions of surfactant pro-
cin in the lung protects against lethal influenza virus infected mice. Virology

316. Schutte BC, McCray PB. 2002. β-Defensins in lung host defense. Annu
Rev Physiol 64:709–748. https://doi.org/10.1146/annurev.physiol.64.081501
134340.

human cathelicidin LL-37 inhibits influenza A viruses through a mecha-

318. Shibata Y, Berclaz PY, Chronou ZC, Yoshida M, Whisette JA, Trappell BC.
2001. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity

https://doi.org/10.1007/s00018-005-3372-0.


Nicolà Clementi, M.S., is Assistant Professor of Medical Microbiology and Virology at University Vita-Salute San Raffaele and Consultant Virologist at the Laboratory of Microbiology and Virology of San Raffaele Hospital, Milan, Italy. His main research interests include the study of hypervariable viruses and their interplay with the antibody response and with antivirals. He is also interested in evaluating the clinical usefulness of next-generation sequencing techniques in the management of viral infections.

Sreya Ghosh completed her Ph.D. in Immunology and Microbiology in 2017 under Dr. Kate Fitzgerald at University of Massachusetts Medical School, Worcester, MA, working on innate immune signaling, inflammasomes, and gene regulation. Thereafter, she joined Dr. Ivan Zanoni’s group at Harvard Medical School and Boston Children’s Hospital as a postdoctoral research fellow, where she works with interferons and immune responses in infectious diseases and cancer. She is interested in understanding how type III interferons affect mucosal immunity and can be harnessed therapeutically in diseases such as respiratory infections and tumorigenesis.

Maria De Santis, M.D., Ph.D., received a degree in Medicine in 2000 and a fellowship in Rheumatology in 2004, both at the Catholic University of Rome, Rome, Italy. She earned the Ph.D. in Proteomics at the University of Verona, Italy, in 2008. She was a medical assistant in the Rheumatology Unit of the Catholic University of Rome between 2004 and 2009. She became a postdoctoral researcher in the BIOMETRA Department at the University of Milan between 2010 and 2015. As of 2016, she is deputy director of the Rheumatology and Clinical Immunology Unit and is responsible for the Scleroderma Unit of the Humanitas Clinical and Research Center in Rozzano, Milan, Italy. Her scientific research focuses on systemic autoimmune and chronic inflammatory diseases with particular interest in systemic sclerosis lung and heart involvement and rheumatoid arthritis pathogenesis.

Matteo Castelli, Ph.D., is a postdoctoral fellow in the Microbiology and Virology Laboratory at the University Vita-Salute San Raffaele, Milan, Italy. He received his Ph.D. in 2016 from the same institution and the Laboratory for Biomolecular Modeling at the École Polytechnique Fédérale de Lausanne, Switzerland, working on the computational modeling of HCV glycoprotein structure. His research interests are focused on the structural and functional characterization of the molecular machineries involved in HCV, HSV, and SARS-CoV-2 entry using experimental and computational techniques.

Elena Criscuolo obtained her Ph.D. in Molecular Medicine at the University Vita-Salute San Raffaele, Milan, Italy, in 2016, working on the antibody response elicited during herpes simplex virus (HSV) infection and the protection conferred in vivo by human monoclonal antibodies. She remained in Massimo Clementi’s Laboratory of Microbiology and Virology as a postdoctoral research fellow, working on synergy evaluation of antiviral drugs acting on different steps of the virus life cycle, on the characterization of sera from HSV-infected subjects, and on modeling HSV reactivation dynamics in a patterned human neuro-keratinocyte circuit reconstituted in a microfluidic device. She then focused on the characterization of entry mechanisms of SARS-CoV-2, the evaluation of antiviral therapies against the infection, and the dissection of the humoral response of COVID-19 patients.

Ivan Zanoni trained with Paola Ricciardi-Castagnoli, receiving his Ph.D. in Immunology from the University of Roma-Tor Vergata, Rome, Italy. He then performed postdoctoral training with Francesca Granucci at the University of Milano-Bicocca, Milan, Italy. Dr. Zanoni is currently Associate Professor at the Faculty of Medicine at Harvard University and Principal Investigator at Boston Children’s Hospital, Division of Immunology, Boston, MA. The Zanoni lab seeks to understand the events that initiate protective immunity in response to infections and tissue injury or that drive the development of immune-mediated diseases.

Massimo Clementi, M.D., is Full Professor of Microbiology and Virology at the University Vita-Salute San Raffaele and chief of the Laboratory of Microbiology and Virology of San Raffaele Hospital, Milan, Italy. Dr. Clementi is a member of the National Scientific Board of the Italian Society of Microbiology (SIM) and founder and past-President of the Italian Society of Medical Virology (SIVIM). Dr. Clementi has research interests in molecular biology of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections, virus-host relationships, microbiology of emerging infectious diseases, infections of immunocompromised patients, and generation and characterization of virus-neutralizing human monoclonal antibodies.

Nicasio Mancini, M.D., is Associate Professor of Medical Microbiology and Virology and Director of Study of the Residency Program in Medical Microbiology and Virology at University Vita-Salute San Raffaele. He is a Medical Microbiologist at the Laboratory of Microbiology and Virology of San Raffaele Hospital, Milan, Italy. He graduated in 2000 from the Catholic University of Rome, Rome, Italy, and was Board Certified in Medical Microbiology and Virology in 2004 by the Università Politecnica delle Marche, Ancona, Italy. His research interests include the study of the interplay between viral pathogens and the humoral immune response and the development and clinical validation of new diagnostic methods in medical microbiology.